US20070199096A1 - Compositions and Methods for Altering Alpha- and Beta-Tocotrienol Content - Google Patents

Abstract

Preparation and use of isolated nucleic acids useful in altering the oil phenotype in plants. Isolated nucleic acids and their encoded polypeptides that alter alpha- and beta-tocotrienol content in seeds and oil obtained from the seeds. Expression cassettes, host cells and transformed plants containing the foregoing nucleic acids.

Description

• This application claims the benefit of U.S. Provisional Application No. 60/736,600, filed Nov. 14, 2005, the entire content of which is herein incorporated by reference.
FIELD OF INVENTION
• The field of the invention relates to plant breeding and molecular biology, and particularly to alteration of oil phenotype in plants through the use of nucleic acid fragments encoding homogentisate geranylgeranyl transferase and gamma-tocopherol methyltransferase.
BACKGROUND
• Tocotrienols are vitamin E-related compounds whose occurrence in plants is limited primarily to the seeds and fruits of most monocot species (e.g., palm, wheat, rice and barley). Tocotrienols are structurally similar to tocopherols, including α-tocopherol or vitamin E, which occur ubiquitously in the plant kingdom as well as in photosynthetic microbes such asSynechocystis.
• Tocotrienols and tocopherols both contain a chromanol head group that is linked to a hydrocarbon side chain. The only structural difference between these molecules is the presence of three double bonds in the hydrocarbon side chain of tocotrienols. This difference is related to the biosynthetic origins of the side chains. Tocopherol side chains are derived from phytyl-pyrophosphate (PP), and the tocotrienol side chains are believed to be derived from geranylgeranyl-PP, seeFIG. 1 andFIG. 2, respectively (Soll et al. (1980)Arch. Biochem. Biophys.204:544-550).
• At least four forms or molecular species of tocopherols and tocotrienols occur in nature: alpha, beta, gamma and delta (α, β, γ and δ, respectively). These molecular species contain different numbers of methyl groups that are bound to the aromatic portion of the chromanol head. Like tocopherols, tocotrienols are potent lipid-soluble antioxidants and therefore have considerable nutritive value in human and animal diets (Packer et al. (2001)J. Nutr.131:369S-373S). In addition, tocotrienols are believed to have therapeutic properties including a demonstrated ability to down regulate cholesterol biosynthesis (Theriault et al. (1999)Clin. Biochem.32:309-319; Qureshii et al. (1986)J. Biol. Chem.261:10544-10550).
• The first committed step in the tocopherol biosynthetic pathway is the prenylation of homogentisic acid with phytyldiphosphate to form 2-methyl-6-phytylbenzoquinol (MPBQ). Two distinct methyltransferase enzymes catalyze methylations of the aromatic moiety of tocopherols (VTE3 and VTE4). 2-methyl-6-phytylbenzoquinol methyltransferase (VTE3) acts on the tocopherol intermediate MPBQ prior to cyclization. Cyclization of the product of the first methylation reaction (2,3-dimethyl-5-phytylbenzoquinol) with tocopherol cyclase (VTE1) provides gamma-tocopherol. Gamma-tocopherol is further methylated to alpha-tocopherol by the second methyltransferase enzyme of tocopherol biosynthesis, gamma-tocopherol methyltransferase (VTE4). The same enzyme methylates delta-tocopherol thereby generating beta-tocopherol.
• It has been speculated that the first committed step in the biosynthesis of tocotrienols involves the condensation of geranylgeranyl-PP and homogentisate to form 2-methyl-6-geranylgeranylbenzoquinol (Soll et al. (1980)Arch. Biochem. Biophys.204:544-550). The enzyme that catalyzes this reaction can thus be functionally described as a homogentisate geranylgeranyl transferase (HGGT). After cyclization and an initial methylation, the last step of tocotrienol production would require the methylation of gamma-tocotrienol to alpha-tocotrienol or delta-tocotrienol to beta-tocotrienol.
• Functional identification of genes or cDNAs encoding homogentisate geranylgeranyl transferase (HGGT) and gamma-tocopherol methyltransferase polypeptides has been reported. However, the use of these nucleic acids in combination to manipulate the biosynthesis of the nutritionally important tocotrienols, such as alpha- and beta-tocotrienol, in plants, seeds and microbial hosts has not yet been reported.
SUMMARY OF THE INVENTION
• Compositions and methods for the alteration of the alpha- and beta-tocotrienol content and composition of plants are provided. The compositions comprise nucleotide molecules comprising nucleotide sequences for HGGT and gamma-tocopherol methyltransferase. The compositions can be used to transform plants to manipulate the synthetic pathway for tocol compounds.
• Transformed plants, plant cells, plant tissues, seed and grain are provided. Transformed plants of the invention find use in methods for improving grain or seed characteristics including, but not limited to, antioxidant level or activity.
• Seeds obtained from such plants and oil obtained from these seeds constitute another aspect of the present invention.
• Expression cassettes comprising sequences of the invention are provided. Isolated polypeptides encoded by the nucleotide sequences of the invention are also provided.
BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE LISTING
• The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.
• FIG. 1 is a schematic depiction of the tocopherol biosynthetic pathway.
• FIG. 2 is a schematic depiction of the tocotrienol biosynthetic pathway.
DETAILED DESCRIPTION
• The combination of HGGT and gamma-tocopherol methyltransferase polynucleotides may be used in plant cells and photosynthetic microbes to alter the tocols, such as tocotrienols, produced in the cells. More specifically, the instant invention shows, inter alia, that the combination of HGGT and gamma-tocopherol methyltransferase polynucleotides may be used to significantly increase the content of vitamin E-related antioxidants, specifically alpha- and beta-tocotrienol, in edible tissues of vegetable, fruit, and agronomic crop plants, including grains such as maize and soybean seed and the oil obtained from these seeds.
• The invention includes compositions and methods for altering tocols. The compositions and methods find use in improving the antioxidant quality of grain for use as food for humans and feed for livestock. Furthermore, the tocols can be extracted, purified or further altered via processing.
• As used herein, “grain” means the mature seed produced by commercial growers for purposes other than reproducing the species and/or immature seed as an integral part of whole plant maize harvested for silage. As used herein, grain includes plant parts commonly categorized as a fruit, nut or vegetable.
• As used herein, “wild-type” refers to untransformed organisms and descendants of untransformed organisms.
• The term “tocol” refers generally to any of the tocopherol and tocotrienol molecular species (e.g., α-, β-, γ-, and δ-) that are known to occur in biological systems. The term “tocol content” refers to the total amount of tocopherol and tocotrienol in a whole plant, tissue, or cell or in a microbial host. The term “tocol composition” refers both to the ratio of the various tocols produced in any given biological system and to characteristics, such as antioxidant activity, of any one tocol compound. When the alteration of tocols is taught or claimed herein, such alteration can be to tocol content and/or tocol composition. When an increase of tocols is taught or claimed herein, such increase refers to an increase of tocol content and/or an increase of tocol activity.
• The term “tocotrienol” refers generally to any of the tocotrienol molecular species (e.g., α, β, γ, and δ) that are known to occur in biological systems. The term “tocotrienol content” refers to the total amount of tocotrienol in a whole plant, tissue, or cell or in a microbial host. The term “tocotrienol composition” refers both to the ratio of the various tocotrienols produced in any given biological system and to characteristics, such as antioxidant activity, of any one tocotrienol compound. When the alteration of a tocotrienol is taught or claimed herein, such alteration can be to tocotrienol content and/or tocotrienol composition. When an increase of tocotrienols is taught or claimed herein, such increase refers to an increase of tocotrienol content and/or an increase of tocotrienol activity.
• The term “homogentisate phytyltransferase” or “HPT” refers to the enzyme that catalyzes the condensation of homogentisate (or homogentisic acid) and phytyl pyrophosphate (or phytyl diphosphate). This reaction is believed to be the committed step in tocopherol biosynthesis. Other names that have been used to refer to this enzyme include “homogentisate phytyl pyrophosphate prenyltransferase” and “homogentisate phytyl diphosphate prenyltransferase”. The shortened version phytyl/prenyl transferase is also used.
• The term “homogentisate geranylgeranyl transferase” or “HGGT” refers to the enzyme that catalyzes the condensation of homogentisate (or homogentisic acid) and geranylgeranyl pyrophosphate (or geranylgeranyl diphosphate). This reaction is an important step in tocotrienol biosynthesis and can result in the alteration of the tocol content and/or composition. HGGT enzymes may include, but are not limited to, those shown in Table 1.

  TABLE 1
  Homogentisate Geranylgeranyl Transferase Enzymes

  SEQ ID NO:

  			(Amino
  Protein	Clone Designation	(Nucleotide)	Acid)

  barley homogentisate	bdl2c.pk006.o2	1	2
  geranylgeranyl transferase
  wheat homogentisate	wdk2c.pk012.f2:cgs	3	4
  geranylgeranyl transferase
  rice homogentisate	rds1c.pk007.m9	5	6
  geranylgeranyl transferase
  maize homogentisate	cco1n.pk087.l17:cgs	7	8
  geranylgeranyl transferase
  maize homogentisate	p0058.chpbj67r:fis	9	10
  geranylgeranyl transferase

• The term “gamma-tocopherol methyltransferase” or “γ-TMT” or “GTMT” (all which may be used interchangeably) refers to the enzyme that catalyzes the methylation of gamma- and delta-tocopherol to alpha- and beta-tocopherol, respectively, and to the methylation of gamma- and delta-tocotrienol to alpha- and beta-tocotrienol, respectively. This reaction is an important step in tocotrienol biosynthesis and can result in the alteration of the tocol content and/or composition. gamma-tocopherol methyltransferase enzymes may include, but are not limited to, those shown in Table 2.

  TABLE 2
  gamma-Tocopherol Methyltransferase Enzymes

  Clone Designation

  SEQ ID NO:

  	or GenBank		(Amino
  Protein	Accession No.	(Nucleotide)	Acid)

  Soybean gamma-tocopherol	sah1c.pk004.g2	11	12
  Methyltransferase
  Soybean gamma-tocopherol	sah1c.pk001.k8:fis	13	14
  Methyltransferase
  maize gamma-tocopherol	p0060.coran49r:fis	15	16
  methyltransferase
  wheat gamma-tocopherol	wr1.pk0077.f1:fis	17	18
  methyltransferase
  lotus corniculatus gamma-	GenBank Accession	19	20
  tocopherol	No. DQ13360
  methyltransferase
  soybean gamma-tocopherol	GenBank Accession	21	22
  methyltransferase	No. AY960126
  rice gamma-tocopherol	GenBank Accession	23	24
  methyltransferase	No. XM467331
  Brassicagamma-tocopherol	GenBank Accession	25	26
  Methyltransferase	No. AF381248
  Perilla frutescens	GenBank Accession	27	28
  gamma-tocopherol	No. AF213481
  methyltransferase
  Arabidopsis thaliana	GenBank Accession	29	30
  gamma-tocopherol	No. AF104220
  methyltransferase
  Medicago truncatula	GenBank Accession	31	32
  gamma-tocopherol	No. AY962639
  Methyltransferase
  Chlamydomonas	GenBank Accession	33	34
  gamma-tocopherol	No. AJ884948
  methyltransferase
  Synechocystis	GenBank Accession	35	36
  gamma-tocopherol	No. NP_442492
  methyltransferase
  Anabaenagamma-	GenBank Accession	37	38
  tocopherol	No. BAB73502
  Methyltransferase
  Gloeobacter violaceus	GenBank Accession	39	40
  gamma-tocopherol	No. NP_926036
  methyltransferase

• Limited information regarding enzymes catalyzing methylations of gamma- and delta-tocotrienol is available. U.S. Application No. 2003154513 discloses sequences derived from cotton, maize and the cyanobacteriaAnabaena. These sequences show similarity to gamma-tocopherol methyltransferase genes fromArabidopsis(PCT Publication No. WO 99/04622) and soybean (PCT Publication No. WO 00/032757). The heterologously expressed enzyme from maize, a moncotyledoneous plant, showed almost equal activity with tocopherol and tocotrienol substrates. On the other hand, gamma-tocopherol methyltransferase orthologs from the dicotyledoneous plant cotton or blue-green algae showed only trace activities with tocotrienol substrates.
• The invention provides isolated nucleotide molecules comprising the combination of nucleotide sequences encoding HGGT and gamma-tocopherol methyltransferase. Also provided are isolated polypeptides encoded by such nucleotide sequences. The nucleotide sequences find use in methods for altering alpha- and beta-tocotrienols in a biological system such as a plant. The methods include improving the antioxidant activity of grain, altering tocotrienols in a plant or part thereof, and improving tocols in a host. The methods comprise transforming a plant or host with at least one nucleotide construct comprising at least a portion of at least one nucleotide sequence encoding HGGT and at least a portion of at least one nucleotide sequence encoding gamma-tocopherol methyltransferase. If desired, the nucleotide construct may additionally comprise at least one operably linked regulatory sequence that drives expression in the plant of interest. Such a nucleotide construct can be used to increase the expression of HGGT and/or gamma-tocopherol methyltransferase.
• Also provided are novel compositions of seed and extracted oils. Seed and extracted oils are provided that have unexpectantly high levels of alpha- and beta-tocotrienol. Seed or oil with high levels of alpha-tocotrienol have better bioavailabilty of alpha-tocotrienol as compared to other tocotrienol species (Kiyose et al. (2004)J. Clin. Biochem. Nutr.35(1):47-52, entitiled—Distribution and metabolism of tocopherols and tocotrienols in vivo).
• Among the many applications of improved tocols, tocotrienols and antioxidant activity are improved storage of grain, improved stability of oil extracted from grain, benefits to humans consuming the grain, improved meat quality from animals consuming the grain, and the production of novel tocols or tocotrienols for cosmetic, industrial and/or nutraceutical use (U.S. Application No. 2004266862; Karunanandaa et al. (2005)Metab. Eng.7:384-400). It is also known that the presence of tocols in plant vegetative green tissue such as leaf tissue is necessary to protect the plant from the photo-oxidative damage induced directly and indirectly by the production of free oxygen radicals in the chloroplast during oxygenic photosynthesis. It is therefore likely that ectopic expression of tocotrienols in green plant tissue, such as leaf tissue, in addition to the normal tocopherol content of the leaf will lead to an increase ability to withstand such photo-oxidative damage, and thus lead to an increase in the photosynthetic capacity of the plant. This would translate to an increase in harvestable yield for the plant over the entire growing season.
• The nucleotide construct of the invention may additionally comprise at least one regulatory sequence that drives expression in a host or plant. Optional regulatory sequences include, for maize, an embryo preferred promoter such as promoters for the 16 kDa and 18 kDa oleosin genes, an endosperm preferred promoter, such as the promoter for the 10 kDa zein gene, and a vegetative promoter such as promoters for ubiquitin genes.
• If desired, two or more of such nucleotide sequences may be linked or joined together to form one polynucleotide molecule, and such a polynucleotide may be used to transform a plant. For example, a nucleotide construct comprising a nucleotide sequence encoding an HGGT can be linked with another nucleotide sequence encoding the same or another HGGT. Nucleotide sequences encoding both HGGT and gamma-tocopherol methyltransferase may also be linked in a nucleotide construct. Similarly, the two nucleotide sequences can be provided on different nucleotide constructs, and each of the separate nucleotide sequences can be operably linked to at least one regulatory sequence that drives expression in a plant. For example, a construct may be used that increases total HGGT activity and decreases total HPT activity, thereby resulting in shunting the pathway towards the production of tocotrienols and decreased production of tocopherols.
• An alternative strategy may also be used. If separate nucleotide constructs are employed for an HGGT nucleotide sequence and a gamma-tocopherol methyltransferase nucleotide sequence, two individual plants may be transformed with the nucleotide constructs, and the plants may then be crossed to produce progeny having the desired genotype of both the HGGT and gamma-tocopherol methyltransferase nucleotide sequences (i.e., also referred to as genetic stacks).
• Additionally, a construct to down-regulate the geranylgeranyl reductase responsible for producing phytol pyrophosphosphate, one of the precursors for tocopherol biosynthesis, may be linked in cis with a construct to express HGGT. The result of this manipulation would be an increased pool size of geranylgeranyl-pyrophosphate and a corresponding increase of flux into the tocotrienol biosynthetic pathway. Flux into tocotrienols can also be increased by increasing flux of carbon into the shikimate pathway and non-mevalonate pathway of isoprenoid biosynthesis. Specifically, this flux can be accomplished through chloroplast-targeted expression of genes such as bifunctional chorismate mutase-prephenate dehydrogenase (TYRA) (from bacteria) and p-hydroxyphenylpyruvate dioxygenase (HPPD) genes from plants (Karunanandaa et al. (2005)Metab. Eng.7:384-400).
• Nucleic acid molecules of the present invention are preferably recombinant nucleic acid molecules (or may also be referred to as recombinant DNA constructs). As used herein, “recombinant” refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques. “Recombinant” also includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid or a cell derived from a cell so modified, but does not encompass the alteration of the cell or vector by naturally occurring events (e.g., spontaneous mutation, natural transformation/transduction/transposition) such as those occurring without deliberate human intervention.
• As used herein, “recombinant DNA construct” refers to a combination of nucleic acid fragments that are not normally found together in nature. Accordingly, a recombinant DNA construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that normally found in nature.
• The methods of the present invention can be employed to alter tocols or tocotrienols in any plant or part thereof, and antioxidant activity may thereby be altered. Plants that may be used in the invention include, but are not limited to, field crops (e.g., alfalfa, barley, bean, maize, cotton, flax, pea, rape, rice, rye, safflower, sorghum, oats, millet, soybean, sunflower, tobacco, and wheat); vegetable crops (e.g., asparagus, beet, broccoli, cabbage, carrot, cauliflower, celery, cucumber, eggplant, lettuce, onion, pepper, potato, pumpkin, radish, spinach, squash, taro, tomato, and zucchini); and fruit and nut crops (e.g., almond, apple, apricot, banana, blackberry, blueberry, cacao, cherry, coconut, cranberry, date, fajoa, filbert, grape, grapefruit, guava, kiwi, lemon, lime, mango, melon, nectarine, orange, papaya, passion fruit, peach, peanut, pear, pineapple, pistachio, plum, raspberry, strawberry, tangerine, walnut, and watermelon) andArabidopsis. Some methods of the invention involve altering the antioxidant levels in grain and other parts of a plant that may be subjected to post-harvest processing. With post-harvest processing, the tocols or tocotrienols so produced can be a valuable source of recovery for millers and other processors.
• Grain or vegetable oil derived from transgenic plants containing elevated levels of alpha- and beta-tocotrienol may be fed to livestock and poultry to improve the oxidative stability of meat products. Examples of improvements with practical benefit include increased color stability of fresh beef during retail display and enhanced flavor stability of precooked meat products stored under refrigeration. These and other quality-related improvements may be expected because tocotrienols function as chain-breaking free radical scavengers in muscle tissue, and thus reduce oxidative reactions that degrade meat quality and reduce shelf life.
• For example, improved beef quality can be demonstrated by feeding cattle a diet formulated with at least about 300-ppm of total alpha- and beta-tocotrienol obtained from high-tocotrienol transgenic grain or vegetable oil for at least 100 days. For comparison, a group of cattle reared on a standard diet (no additional tocotrienol) under otherwise identical conditions can serve as the control treatment (“control group”). To assess fresh meat color stability, ribeye steaks harvested from each animal are individually packaged in foam trays with PVC overwrap and placed under simulated retail display for seven days. Fresh steak color is subjectively evaluated by trained panelists on a graded scale for visual color intensity and discoloration. Color is also evaluated instrumentally using a HunterLab MiniScan™ Spectrophotometer or similar device to assess the “a* value”, which is a measure of the degree of redness. Results of these assays demonstrate that over time steaks from cattle fed a high tocotrienol diet, on average, exhibit better subjective visual scores and higher (i.e., better) a* instrumental values than ribeye steaks from the control group over time. The improvement in color stability extends retail display time and thus reduces the amount of fresh product discounted and discarded due to color deterioration. Other fresh beef products, including ground beef, will also exhibit improved color stability with and thus provide a similar benefit to retailers. (See also WO Publication No. 2005/002358, herein incorporated in its entirety by reference).
• Methods for assessing tocopherol content and tocopherol composition (including tocopherol activity) are known in the art. Tocopherol content and composition may be measured by HPLC in combination with fluorescence detection. Such methods are described in numerous literature references (e.g., Kamal-Eldi A., Gorgen S., Pettersson J., Lampi A. M. (2000)J. Chromatogr. A881:217-227; Bonvehi J. S., Coil F. V., Rius I. A. (2000)J. AOAC Intl.83:627-634; Goffman F. D. and Böhme T. (2001)J. Agric. Food Chem.49:4990-4994). Such methods typically involve the resolution of tocopherol molecular species contained in complex mixtures by use of a normal or reverse phase HPLC matrix. Eluted tocopherol molecular species are then detected by fluorescence of the chromanol head group with an excitation wavelength typically in the range of 290 to 295 nm and an emission wavelength typically in the range of 325 to 335 nm. Using this methodology, the composition of a tocopherol mixture can be determined by comparing the retention times of separated molecular species with those of known standards. The content of each tocopherol molecular species can be measured by the relative intensity of its fluorescence emission at the selected wavelength. The absolute amount of each tocopherol species can be determined by measuring the intensity of fluorescence emission relative to that of an internal standard, which is added in a known amount to the tocopherol mixture prior to HPLC analysis. A suitable internal standard can include a tocopherol analog that is not normally found in nature (e.g., 5,7-dimethyltocol) or a naturally occurring tocopherol molecular species that is not present in a given tocopherol mixture. The total tocopherol content of a complex mixture of compounds can be derived by summing the absolute amount of each of the component tocopherol molecular species as determined by HPLC analysis.
• Methods for assessing tocotrienol content and tocotrienol composition (including tocotrienol activity) are known in the art. Tocotrienol content and composition may be measured by HPLC using methods described above for the analysis of tocopherol content and composition. Using HPLC techniques described in Example 3 and elsewhere (e.g., Podda M., Weber C., Traber M. G., Packer L. (1996)J. Lipid Res.37:893-901), tocotrienol molecular species can be readily resolved from tocopherol molecular species in a complex mixture. The occurrence and structural identification of tocotrienols in a complex mixture can be determined by gas chromatography-mass spectrometry as described by Frega N., Mozzon M., and Bocci F. (1998)J. Amer. Oil Chem. Soc.75:1723-1728.
• In addition, lipophilic antioxidant activity may be measured by assays including the inhibition of the coupled auto-oxidation of linoleic acid and β-carotene and oxygen radical absorbance capacity (ORAC) as described elsewhere (Serbinova E. A. and Packer L. (1994)Meth. Enzymol.234:354-366; Emmons C. L., Peterson D. M., Paul G. L. (1999)J. Agric. Food Chem.47:4894-4898); Huang D et al (2002)J. Agric. Food Chem.). Such methods typically involve measuring the ability of antioxidant compounds (i.e., tocols) in test materials to inhibit the decline of fluorescence of a model substrate (fluorescein, phycoerythrin) induced by a peroxyl radical generator (2′,2′-azobis[20amidinopropane]dihydrochloride).
• The invention encompasses isolated or substantially purified nucleic acid or polypeptide compositions. An “isolated” or “purified” nucleic acid molecule or polypeptide, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Preferably, an “isolated” nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, 0.3 kb or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A polypeptide that is substantially free of cellular material includes preparations of polypeptide having less than about 30%, 20%, 10%, 5%, (by dry weight) of contaminating polypeptide. When the polypeptide of the invention or biologically active portion thereof is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, 5%, 3% or 1% (by dry weight) of chemical precursors or non-polypeptide-of-interest chemicals.
• Fragments and variants of the disclosed nucleotide sequences and polypeptides encoded thereby are also encompassed by the present invention. By “fragment” is intended a portion of the nucleotide sequence or a portion of the amino acid sequence. Functional fragments of a nucleotide sequence may encode polypeptide fragments that retain the biological activity of the native protein and hence HGGT activity and/or gamma-tocopherol methyltransferase activity. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes generally do not encode polypeptides retaining biological activity. Thus, fragments of a nucleotide sequence may range from at least about 20 nucleotides, about 30 nucleotides, about 50 nucleotides, about 70 nucleotides, about 100 nucleotides, about 150 nucleotides and up to the full-length nucleotide sequence encoding the polypeptides of the invention.
• A fragment of a HGGT nucleotide sequence that encodes a biologically active portion of an HGGT polypeptide of the invention will encode at least 15, 25, 30, 50, 75, 100, or 125 contiguous amino acids, or up to the total number of amino acids present in a full-length HGGT polypeptide of the invention (for example, 407, 408, 404, 380 and 361 amino acids for SEQ ID NO:2, 4, 6, 8 and 10, respectively). Fragments of a HGGT nucleotide sequence that are useful as hybridization probes or PCR primers generally need not encode a biologically active portion of an HGGT polypeptide.
• Thus, a fragment of an HGGT nucleotide sequence may encode a biologically active portion of an HGGT polypeptide, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of an HGGT polypeptide can be prepared by isolating a portion of one of the HGGT nucleotide sequences of the invention, expressing the encoded portion of the HGGT polypeptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the HGGT polypeptide.
• Nucleic acid molecules that are fragments of an HGGT nucleotide sequence comprise at least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, or 700 nucleotides, or up to the number of nucleotides present in a full-length HGGT nucleotide sequence disclosed herein (for example, 1457, 1365, 1242, 1730, and 1769 nucleotides for SEQ ID NO:1, 3, 5, 7 and 9, respectively).
• Likewise, a fragment of a gamma-tocopherol methyltransferase nucleotide sequence that encodes a biologically active portion of a gamma-tocopherol methyltranferase polypeptide of the invention will encode at least 15, 25, 30, 50, 75, 100, or 125 contiguous amino acids, or up to the total number of amino acids present in a full-length gamma-tocopherol methyltranferase polypeptide of the invention. Fragments of a gamma-tocopherol methyltranferase nucleotide sequence that are useful as hybridization probes or PCR primers generally need not encode a biologically active portion of a gamma-tocopherol methyltransferase polypeptide.
• Thus, a fragment of an gamma-tocopherol methyltranferase nucleotide sequence may encode a biologically active portion of an gamma-tocopherol methyltranferase polypeptide, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of an gamma-tocopherol methyltranferase polypeptide can be prepared by isolating a portion of one of the gamma-tocopherol methyltranferase nucleotide sequences of the invention, expressing the encoded portion of the gamma-tocopherol methyltranferase polypeptide (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of the gamma-tocopherol methyltranferase polypeptide.
• Nucleic acid molecules that are fragments of an gamma-tocopherol methyltranferase nucleotide sequence comprise at least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, or 700 nucleotides, or up to the number of nucleotides present in a full-length gamma-tocopherol methyltranferase nucleotide sequence disclosed herein.
• By “variants” is intended substantially similar sequences. For nucleotide sequences, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the HGGT and/or gamma-tocopherol methyltransferase polypeptides of the invention. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis but which still encode an HGGT and/or gamma-tocopherol methyltransferase polypeptide of the invention. Generally, variants of a particular nucleotide sequence of the invention will have at least about 80% generally at least about 85%, preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to that particular nucleotide sequence as determined by sequence alignment programs described elsewhere herein using default parameters.
• By “variant” polypeptide is intended a polypeptide derived from the native polypeptide by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native polypeptide; deletion or addition of one or more amino acids at one or more sites in the native polypeptide; or substitution of one or more amino acids at one or more sites in the native polypeptide. Variant polypeptides encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native polypeptide, that is, HGGT and/or gamma-tocopherol methyltransferase activity as described herein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native HGGT and/or gamma-tocopherol methyltransferase polypeptide of the invention will have at least about 60%, 65%, 70%, generally at least about 75%, 80%, 85%, preferably at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, and more preferably at least about 98%, 99% or more sequence identity to the amino acid sequence for the native polypeptide as determined by sequence alignment programs described elsewhere herein using default parameters. A biologically active variant of a polypeptide of the invention may differ from that polypeptide by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.
• The polypeptides of the invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of the HGGT and/or gamma-tocopherol methyltransferase polypeptides can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985)Proc. Natl. Acad. Sci. USA82:488-492; Kunkel et al. (1987)Methods in Enzymol.154:367-382; U.S. Pat. No. 4,873,192; Walker and Gaastra, eds. (1983)Techniques in Molecular Biology(MacMillan Publishing Company, New York) and the references cited therein. Guidance as to appropriate amino acid substitutions that do not affect biological activity of the polypeptide of interest may be found in the model of Dayhoff et al. (1978)Atlas of Protein Sequence and Structure(Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferred.
• Thus, the genes and nucleotide sequences of the invention include both the naturally occurring sequences as well as mutant forms. Likewise, the polypeptides of the invention encompass both naturally occurring polypeptides as well as variations and modified forms thereof. Such variants will continue to possess the desired HGGT and/or gamma-tocopherol methyltransferase activity. Preferably, the mutations that will be made in the DNA encoding the variant will not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. See, EP Patent Application Publication No. 75,444.
• The deletions, insertions, and substitutions of the polypeptide sequences encompassed herein are not expected to produce radical changes in the characteristics of the polypeptide. However, when it is difficult to predict the exact effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. That is, the activity can be evaluated by assays for HGGT and/or gamma-tocopherol methyltransferase activity.
• Variant nucleotide sequences and polypeptides also encompass sequences and polypeptides derived from a mutagenic and recombinogenic procedure such as DNA shuffling. With such a procedure, one or more different HGGT and/or gamma-tocopherol methyltransferase coding sequences can be manipulated to create a new HGGT and/or gamma-tocopherol methyltransferase polypeptide possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously recombined in vitro or in vivo. For example, using this approach, sequence motifs encoding a domain of interest may be shuffled between the HGGT polynucleotides of the invention and/or other HGGT genes to obtain a new gene coding for a polypeptide with an improved property of interest, such as an increased K_min the case of an enzyme. Likewise, using this approach, sequence motifs encoding a domain of interest may be shuffled between the gamma-tocopherol methyltransferase polynucleotides of the invention and/or other gamma-tocopherol methyltransferase genes to obtain a new gene coding for a polypeptide with an improved property of interest, such as an increased K_min the case of an enzyme. Strategies for such DNA shuffling are known in the art. See, for example, Stemmer (1994)Proc. Natl. Acad. Sci. USA91:10747-10751; Stemmer (1994)Nature370:389-391; Crameri et al. (1997)Nature Biotech.15:436-438; Moore et al. (1997)J. Mol. Biol.272:336-347; Zhang et al. (1997)Proc. Natl. Acad. Sci. USA94:4504-4509; Crameri et al. (1998)Nature391:288-291; and U.S. Pat. Nos. 5,605,793 and 5,837,458.
• The nucleotide sequences of the invention can be used to isolate corresponding sequences from other organisms, particularly other plants, more particularly other monocots or dicots. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequences set forth herein. Sequences isolated based on their sequence identity to the entire HGGT and/or gamma-tocopherol methyltransferase nucleotide sequences set forth herein or to fragments thereof are encompassed by the present invention. Such sequences include sequences that are orthologs of the disclosed sequences. By “orthologs” is intended polynucleotides derived from a common ancestral gene and which are found in different species as a result of speciation. Polynucleotides found in different species are considered orthologs when their nucleotide sequences and/or their encoded polypeptide sequences share substantial identity as defined elsewhere herein. Functions of orthologs are often highly conserved among species.
• In a PCR approach, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any plant of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989)Molecular Cloning: A Laboratory Manual(2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.). See also Innis et al., eds. (1990)PCR Protocols:A Guide to Methods and Applications(Academic Press, New York); Innis and Gelfand, eds. (1995)PCR Strategies(Academic Press, New York); and Innis and Gelfand, eds. (1999)PCR Methods Manual(Academic Press, New York). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially-mismatched primers, and the like.
• For clarification, “PCR” or “polymerase chain reaction” is a technique for the synthesis of large quantities of specific DNA segments, and consists of a series of repetitive cycles (Perkin Elmer Cetus Instruments, Norwalk, Conn.). Typically, the double stranded DNA is heat denatured, the two primers complementary to the 3′ boundaries of the target segment are annealed at low temperature and then extended at an intermediate temperature. One set of these three consecutive steps is referred to as a cycle.
• In hybridization techniques, all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments, RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as³²P, or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the HGGT and/or gamma-tocopherol methyltransferase sequences of the invention. Methods for preparation of probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in Sambrook et al. (1989)Molecular Cloning: A Laboratory Manual(2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.).
• For example, an entire HGGT and/or gamma-tocopherol methyltransferase sequence disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding HGGT and/or gamma-tocopherol methyltransferase sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique among HGGT and/or gamma-tocopherol methyltransferase sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify corresponding HGGT and/or gamma-tocopherol methyltransferase sequences from a chosen plant by PCR. This technique may be used to isolate additional coding sequences from a desired plant or as a diagnostic assay to determine the presence of coding sequences in a plant. Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, Sambrook et al. (1989)Molecular Cloning: A Laboratory Manual(2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.).
• Hybridization of such sequences may be carried out under stringent conditions. By “stringent conditions” or “stringent hybridization conditions” is intended conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length.
• Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37° C., and a wash in 1× to 2×SSC (20×SSC=3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37° C., and a wash in 0.5× to 1×SSC at 55 to 60° C. Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 0.1×SSC at 60 to 65° C. The duration of hybridization is generally less than about 24 hours, usually about 4 to about 12 hours.
• Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_mcan be approximated from the equation of Meinkoth and Wahl (1984)Anal. Biochem.138:267-284: T_m=81.5° C.+16.6 (log M)+0.41 (% GC)−0.61 (% form)−500/L; where M is the molarity of monovalent cations, % GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. The T_mis the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_mis reduced by about 1° C. for each 1% of mismatching; thus, T_m, hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with ≧90% identity are sought, the T_mcan be decreased 10° C. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4° C. lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10° C. lower than the thermal melting point (T_m); low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20° C. lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m, those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_mof less than 45° C. (aqueous solution) or 32° C. (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993)Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, N.Y.); and Ausubel et al., eds. (1995)Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley-Interscience, New York). See Sambrook et al. (1989)Molecular Cloning: A Laboratory Manual(2d ed., Cold Spring Harbor Laboratory Press, Plainview, N.Y.).
• Isolated sequences that encode for a HGGT and/or gamma-tocopherol methyltransferase polypeptide and which hybridize under stringent conditions to the HGGT and/or gamma-tocopherol methyltransferase sequences disclosed herein, or to fragments thereof, are encompassed by the present invention.
• Nucleotides (usually found in their T-monophosphate form) are often referred to herein by their single letter designation as follows: “A” for adenylate or deoxyadenylate (for RNA or DNA, respectively), “C” for cytidylate or deoxycytidylate, “G” for guanylate or deoxyguanylate, “U” for uridylate, “T” for deoxythymidylate, “R’ for purines (A or G), “Y” for pyrimidines (C or T), “K” for G or T, “W” for A or T, “H” for A or C or T, “D” for A or G or T, “M” for A or C, “S” for C or G, “V” for A or C or G, “B” for C or G or T “I” for inosine, and “N” for A, C, G, or T.
• The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) “reference sequence”, (b) “comparison window”, (c) “sequence identity”, (d) “percentage of sequence identity”, and (e) “substantial identity”.
• (a) As used herein, “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
• (b) As used herein, “comparison window” makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches.
• Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent identity between any two sequences can be accomplished using a mathematical algorithm. Non-limiting examples of such mathematical algorithms are the algorithm of Myers and Miller (1988)CABIOS4:11-17; the local homology algorithm of Smith et al. (1981)Adv. Appl. Math.2:482; the homology alignment algorithm of Needleman and Wunsch (1970)J. Mol. Biol.48:443-453; the search-for-similarity-method of Pearson and Lipman (1988)Proc. Natl. Acad. Sci.85:2444-2448; the algorithm of Karlin and Altschul (1990)Proc. Natl. Acad. Sci. USA87:2264-2268, modified as in Karlin and Altschul (1993)Proc. Natl. Acad. Sci. USA90:5873-5877.
• Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, Calif.); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wis., USA). Alignments using these programs can be performed using the default parameters. The CLUSTAL program is well described by Higgins et al. (1988)Gene73:237-244 (1988); Higgins et al. (1989)CABIOS5:151-153; Corpet et al. (1988)Nucleic Acids Res.16:10881-90; Huang et al. (1992)CABIOS8:155-65; and Pearson et al. (1994)Meth. Mol. Biol.24:307-331. The ALIGN program is based on the algorithm of Myers and Miller (1988), supra. A PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used with the ALIGN program when comparing amino acid sequences. The BLAST programs of Altschul et al. (1990)J. Mol. Biol.215:403 are based on the algorithm of Karlin and Altschul (1990), supra. BLAST nucleotide searches can be performed with the BLASTN program, score=100, wordlength=12, to obtain nucleotide sequences homologous to a nucleotide sequence encoding a polypeptide of the invention. BLAST polypeptide searches can be performed with the BLASTX program, score=50, wordlength=3, to obtain amino acid sequences homologous to a polypeptide of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST (in BLAST 2.0) can be utilized as described in Altschul et al. (1997)Nucleic Acids Res.25:3389. Alternatively, PSI-BLAST (in BLAST 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See Altschul et al. (1997) supra. When utilizing BLAST, Gapped BLAST, PSI-BLAST, the default parameters of the respective programs (e.g., BLASTN for nucleotide sequences, BLASTX for polypeptides) can be used. Alignment may also be performed manually by inspection.
• Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP Version 10 using the following parameters: % identity using GAP Weight of 50 and Length Weight of 3; % similarity using Gap Weight of 12 and Length Weight of 4, or any equivalent program. By “equivalent program” is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by the preferred program.
• GAP uses the algorithm of Needleman and Wunsch (1970)J. Mol. Biol.48: 443-453, to find the alignment of two complete sequences that maximizes the number of matches and minimizes the number of gaps. GAP considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. It allows for the provision of a gap creation penalty and a gap extension penalty in units of matched bases. GAP must make a profit of gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is chosen, GAP must, in addition, make a profit for each gap inserted of the length of the gap times the gap extension penalty. Default gap creation penalty values and gap extension penalty values in Version 10 of the Wisconsin Genetics Software Package for polypeptide sequences are 8 and 2, respectively. For nucleotide sequences the default gap creation penalty is 50 while the default gap extension penalty is 3. The gap creation and gap extension penalties can be expressed as an integer selected from the group of integers consisting of from 0 to 200. Thus, for example, the gap creation and gap extension penalties can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or greater.
• GAP presents one member of the family of best alignments. There may be many members of this family, but no other member has a better quality. GAP displays four figures of merit for alignments: Quality, Ratio, Identity, and Similarity. The Quality is the metric maximized in order to align the sequences. Ratio is the quality divided by the number of bases in the shorter segment. Percent Identity is the percent of the symbols that actually match. Percent Similarity is the percent of the symbols that are similar. Symbols that are across from gaps are ignored. A similarity is scored when the scoring matrix value for a pair of symbols is greater than or equal to 0.50, the similarity threshold. The scoring matrix used in Version 10 of the Wisconsin Genetics Software Package is BLOSUM62 (see Henikoff and Henikoff (1989)Proc. Natl. Acad. Sci. USA89:10915).
• Alternatively, for purposes of the present invention, comparison of nucleotide or polypeptide sequences for determination of percent sequence identity to the HGGT or gamma-tocopherol methyltransferase sequences disclosed herein is preferably made using CLUSTAL with the following changes from the default parameters. For amino acid sequence comparisons a Gap Penalty of 10 and Gap Length Penalty of 10 was used for multiple alignments and a KTUPLE of 2, Gap Penalty of 3, Window of 5 and Diagonals Saved of 5 was used for pairwise alignments. For nucleotide sequence comparisons, a Gap Penalty of 10 and Gap Length Penalty of 10 was used for multiple alignments and a KTUPLE of 2, Gap Penalty of 5, Window of 4 and Diagonals Saved of 4 was used for pairwise alignments. Any equivalent program can also be used to determine percent sequence identity. By “equivalent program” is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by the preferred program.
• (c) As used herein, “sequence identity” or “identity” in the context of two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to polypeptides it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have “sequence similarity” or “similarity”. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).
• (d) As used herein, “percentage of sequence identity” means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.
• (e)(i) The term “substantial identity” of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90%, and most preferably at least 95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of polypeptides encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.
• Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1° C. to about 20° C. lower than the T_m, depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.
• (e)(ii) The term “substantial identity” in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (1970)J. Mol. Biol.48:443-453. An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides that are “substantially similar” share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes.
• The use of the term “nucleotide constructs” herein is not intended to limit the present invention to nucleotide constructs comprising DNA. Those of ordinary skill in the art will recognize that nucleotide constructs, particularly polynucleotides and oligonucleotides, comprised of ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides may also be employed in the methods disclosed herein. Thus, the nucleotide constructs of the present invention encompass all nucleotide constructs that can be employed in the methods of the present invention for transforming plants including, but not limited to, those comprised of deoxyribonucleotides, ribonucleotides, and combinations thereof. Such deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. The nucleotide constructs of the invention also encompass all forms of nucleotide constructs including, but not limited to, single-stranded forms, double-stranded forms, hairpins, stem-and-loop structures, and the like.
• Furthermore, it is recognized that the methods of the invention may employ a nucleotide construct that is capable of directing, in a transformed plant, the expression of at least one polypeptide, or at least one RNA, such as, for example, an antisense RNA that is complementary to at least a portion of an mRNA. Typically such a nucleotide construct is comprised of a coding sequence for a polypeptide or an RNA operably linked to 5′ and 3′ transcriptional regulatory regions. Alternatively, it is also recognized that the methods of the invention may employ a nucleotide construct that is not capable of directing, in a transformed plant, the expression of a polypeptide or an RNA.
• In addition, it is recognized that methods of the present invention do not depend on the incorporation of the entire nucleotide construct into the genome, only that the plant or cell thereof is altered as a result of the introduction of the nucleotide construct into a cell. In one embodiment of the invention, the genome may be altered following the introduction of the nucleotide construct into a cell. For example, the nucleotide construct, or any part thereof, may incorporate into the genome of the plant. Alterations to the genome of the present invention include, but are not limited to, additions, deletions, and substitutions of nucleotides in the genome. While the methods of the present invention do not depend on additions, deletions, or substitutions of any particular number of nucleotides, it is recognized that such additions, deletions, or substitutions comprise at least one nucleotide.
• The nucleotide constructs of the invention also encompass nucleotide constructs that may be employed in methods for altering or mutating a genomic nucleotide sequence in an organism, including, but not limited to, homologous recombination, chimeric vectors, chimeric mutational vectors, chimeric repair vectors, mixed-duplex oligonucleotides, self-complementary chimeric oligonucleotides, and recombinogenic oligonucleobases. See, U.S. Pat. Nos. 5,565,350; 5,731,181; 5,756,325; 5,760,012; 5,795,972; and 5,871,984; all of which are herein incorporated by reference. See also, PCT Publication No. WO 98/49350, PCT Publication No. WO 99/07865, PCT Publication No. WO 99/25821, PCT Publication No. WO03093428, Jeske et al. (2001)EMBO20:6158-6167, and Beetham et al. (1999)Proc. Natl. Acad. Sci. USA96:8774-8778; herein incorporated by reference.
• The HGGT and gamma-tocopherol methyltransferase sequences of the invention are provided in expression cassettes for expression in the plant of interest. The cassette(s) will include at least one 5′ and 3′ regulatory sequences operably linked to a HGGT and/or gamma-tocopherol methyltransferase nucleotide sequence of the invention. By “operably linked” is intended a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two polypeptide coding regions, contiguous and in the same reading frame. The cassette may additionally contain at least one additional gene to be cotransformed into the organism. Alternatively, the additional gene(s) can be provided on multiple expression cassettes.
• Such an expression cassette is provided with a plurality of restriction sites for insertion of the HGGT and/or gamma-tocopherol methyltransferase nucleotide sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.
• The expression cassette will include in the 5′-3′ direction of transcription, a transcriptional and translational initiation region, a HGGT and/or gamma-tocopherol methyltransferase polynucleotide sequence of the invention, and a transcriptional and translational termination region functional in plants. The transcriptional initiation region, the promoter, may be native or analogous or foreign or heterologous to the plant host. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By “foreign” is intended that the transcriptional initiation region is not found in the native plant into which the transcriptional initiation region is introduced. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.
• While it may be preferable to express the sequences using heterologous promoters, the native promoter sequences may be used. Such constructs would change expression levels of HGGT and/or gamma-tocopherol methyltransferase in the plant, plant cell or other host. Thus, the phenotype of the plant, plant cell or other host is altered.
• The termination region may be native with the transcriptional initiation region, may be native with the operably linked DNA sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid ofA. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991)Mol. Gen. Genet.262:141-144; Proudfoot (1991)Cell64:671-674; Sanfacon et al. (1991)Genes Dev.5:141-149; Mogen et al. (1990)Plant Cell2:1261-1272; Munroe et al. (1990)Gene91:151-158; Ballas et al. (1989)Nucleic Acids Res.17:7891-7903; and Joshi et al. (1987)Nucleic Acid Res.15:9627-9639.
• Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. See, for example, Campbell and Gowri (1990)Plant Physiol.92:1-11 for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Pat. Nos. 5,380,831, and 5,436,391, and Murray et al. (1989)Nucleic Acids Res.17:477-498, herein incorporated by reference.
• Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.
• The expression cassettes may additionally contain 5′ leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5′ noncoding region) (Elroy-Stein et al. (1989)Proc. Natl. Acad. Sci. USA86:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Gallie et al. (1995)Gene165(2):233-238), MDMV leader (Maize Dwarf Mosaic Virus) (Virology154:9-20), and human immunoglobulin heavy-chain binding protein (BiP) (Macejak et al. (1991)Nature353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (Jobling et al. (1987)Nature325:622-625); tobacco mosaic virus leader (TMV) (Gallie et al. (1989) inMolecular Biology of RNA, ed. Cech (Liss, New York), pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et al. (1991)Virology81:382-385). See also, Della-Cioppa et al. (1987)Plant Physiol.84:965-968. Other methods known to enhance translation can also be utilized, for example, introns, and the like.
• In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved.
• A number of promoters can be used in the practice of the invention. The promoters can be selected based on the desired outcome. The nucleic acids can be combined with constitutive, chemically regulated, tissue-preferred, or other promoters for expression in plants.
• Such constitutive promoters include, for example, the core promoter of the Rsyn7 promoter and other constitutive promoters disclosed in PCT Publication No. WO 99/43838 and U.S. Pat. No. 6,072,050; the core CaMV 35S promoter (Odell et al. (1985)Nature313:810-812); rice actin (McElroy et al. (1990)Plant Cell2:163-171); ubiquitin (Christensen et al. (1989)Plant Mol. Biol.12:619-632 and Christensen et al. (1992)Plant Mol. Biol.18:675-689); pEMU (Last et al. (1991)Theor. Appl. Genet.81:581-588); MAS (Velten et al. (1984)EMBO J.3:2723-2730); ALS promoter (U.S. Pat. No. 5,659,026), and the like. Other constitutive promoters include, for example, U.S. Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611.
• Chemically regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical inducible promoter, where application of the chemical induces gene expression, or a chemical repressible promoter, where application of the chemical represses gene expression. Chemical inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-1a promoter, which is activated by salicylic acid. Other chemically regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena et al. (1991)Proc. Natl. Acad. Sci. USA88:10421-10425 and McNellis et al. (1998)Plant J.14(2):247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz et al. (1991)Mol. Gen. Genet.227:229-237, and U.S. Pat. Nos. 5,814,618 and 5,789,156), herein incorporated by reference.
• Tissue-preferred promoters can be utilized to target enhanced HGGT and/or gamma-tocopherol methyltransferase expression within a particular plant tissue. Tissue-preferred promoters include Yamamoto et al. (1997)Plant J.12(2):255-265; Kawamata et al. (1997)Plant Cell Physiol.38(7):792-803; Hansen et al. (1997)Mol. Gen. Genet.254(3):337-343; Russell et al. (1997)Transgenic Res.6(2):157-168; Rinehart et al. (1996)Plant Physiol.112(3):1331-1341; Van Camp et al. (1996)Plant Physiol.112(2):525-535; Canevascini et al. (1996)Plant Physiol.112(2):513-524; Yamamoto et al. (1994)Plant Cell Physiol.35(5):773-778; Lam (1994)Results Probl. Cell Differ.20:181-196; Orozco et al. (1993)Plant Mol. Biol.23(6):1129-1138; Matsuoka et al. (1993)Proc Natl. Acad. Sci. USA90(20):9586-9590; and Guevara-Garcia et al. (1993)Plant J.4(3):495-505. Such promoters can be modified, if necessary, for weak expression.
• Leaf-preferred promoters are known in the art. See, for example, Yamamoto et al. (1997)Plant J.12(2):255-265; Kwon et al. (1994)Plant Physiol.105:357-67; Yamamoto et al. (1994)Plant Cell Physiol.35(5):773-778; Gotor et al. (1993)Plant J.3:509-18; Orozco et al. (1993)Plant Mol. Biol.23(6):1129-1138; and Matsuoka et al. (1993)Proc. Natl. Acad. Sci. USA90(20):9586-9590.
• Root-preferred promoters are known and can be selected from the many available from the literature or isolated de novo from various compatible species. See, for example, Hire et al. (1992)Plant Mol. Biol.20(2): 207-218 (soybean root-preferred glutamine synthetase gene); Keller and Baumgartner (1991)Plant Cell3(10):1051-1061 (root-preferred control element in the GRP 1.8 gene of French bean); Sanger et al. (1990)Plant Mol. Biol.14(3):433-443 (root-preferred promoter of the mannopine synthase (MAS) gene ofAgrobacterium tumefaciens); and Miao et al. (1991)Plant Cell3(1):11-22 (full-length cDNA clone encoding cytosolic glutamine synthetase (GS), which is expressed in roots and root nodules of soybean). See also Bogusz et al. (1990)Plant Cell2(7):633-641, where two root-preferred promoters isolated from hemoglobin genes from the nitrogen-fixing nonlegumeParasponia andersoniiand the related non-nitrogen-fixing nonlegumeTrema tomentosaare described. The promoters of these genes were linked to a β-glucuronidase reporter gene and introduced into both the nonlegumeNicotiana tabacumand the legumeLotus corniculatus, and in both instances root-preferred promoter activity was preserved. Leach and Aoyagi (1991) describe their analysis of the promoters of the highly expressed roIC and roID root-inducing genes ofAgrobacterium rhizogenes(seePlant Science(Limerick) 79(1):69-76). They concluded that enhancer and tissue-preferred DNA determinants are dissociated in those promoters. Teeri et al. (1989) used gene fusion to lacZ to show that theAgrobacteriumT-DNA gene encoding octopine synthase is especially active in the epidermis of the root tip and that the TR2′ gene is root preferred in the intact plant and stimulated by wounding in leaf tissue, an especially desirable combination of characteristics for use with an insecticidal or larvicidal gene (seeEMBO J.8(2):343-350). The TR1′ gene, fused to nptII (neomycin phosphotransferase II) showed similar characteristics. Additional root-preferred promoters include the VfENOD-GRP3 gene promoter (Kuster et al. (1995)Plant Mol. Biol.29(4):759-772); and roIB promoter (Capana et al. (1994)Plant Mol. Biol.25(4):681-691. See also U.S. Pat. Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732; and 5,023,179.
• “Seed-preferred” promoters include both “seed-specific” promoters (those promoters active during seed development such as promoters of seed storage proteins) as well as “seed-germinating” promoters (those promoters active during seed germination). See Thompson et al. (1989)BioEssays10:108, herein incorporated by reference. Such seed-preferred promoters include, but are not limited to, Cim1 (cytokinin-induced message); cZ19B1 (maize 19 kDa zein); milps (myo-inositol-1-phosphate synthase) (see WO 00/11177 and U.S. Pat. No. 6,225,529; herein incorporated by reference). Gamma-zein is an endosperm-specific promoter. Globulin 1 (Glb-1) is a representative embryo-specific promoter. For dicots, seed-specific promoters include, but are not limited to, bean β-phaseolin, napin, β-conglycinin, soybean lectin, cruciferin, and the like. For monocots, seed-specific promoters include, but are not limited to, maize 15 kDa zein, 22 kDa zein, 27 kDa zein, gamma-zein, waxy, shrunken 1, shrunken 2, Globulin 1, etc. See also the promoters found in the following: End1 and End2 (WO 00/12733), Lec1 (WO 2002/42424), Jip1 (WO 2002/42424), EAP1 (U.S. Patent Publication No. 2004/0210043), ODP2 (U.S. Patent Publication No. 2005/0223432); all of which are herein incorporated by reference.
• In one embodiment, the nucleic acids of interest are targeted to the chloroplast for expression. In this manner, where the nucleic acid of interest is not directly inserted into the chloroplast, the expression cassette will additionally contain a nucleic acid encoding a transit peptide to direct the gene product of interest to the chloroplasts or other plastids. Such transit peptides are known in the art. See, for example, Von Heijne et al. (1991)Plant Mol. Biol. Rep.9:104-126; Clark et al. (1989)J. Biol. Chem.264:17544-17550; Della-Cioppa et al. (1987)Plant Physiol.84:965-968; Romer et al. (1993)Biochem. Biophys. Res. Commun.196:1414-1421; and Shah et al. (1986)Science233:478-481.
• The HGGT and/or gamma-tocopherol methyltransferase polypeptides of the invention can be targeted to specific compartments within the plant cell. Methods for targeting polypeptides to a specific compartment are known in the art. Generally, such methods involve modifying the nucleotide sequence encoding the polypeptide in such a manner as to add or remove specific amino acids from the polypeptide encoded thereby. Such amino acids comprise targeting signals for targeting the polypeptide to a specific compartment such as, for example, a the plastid, the nucleus, the endoplasmic reticulum, the vacuole, the mitochondrion, the peroxisome, the Golgi apparatus, and for secretion from the cell. Targeting sequences for targeting a polypeptide to a specific cellular compartment, or for secretion, are known to those of ordinary skill in the art. Chloroplast-targeting or plastid-targeting sequences are known in the art and include the chloroplast small subunit of ribulose-1,5-bisphosphate carboxylase (Rubisco) (de Castro Silva Filho et al. (1996)Plant Mol. Biol.30:769-780; Schnell et al. (1991)J. Biol. Chem.266(5):3335-3342); 5-(enolpyruvyl)shikimate-3-phosphate synthase (EPSPS) (Archer et al. (1990)J. Bioenerg. Biomemb.22(6):789-810); tryptophan synthase (Zhao et al. (1995)J. Biol. Chem.270(11):6081-6087); plastocyanin (Lawrence et al. (1997)J. Biol. Chem.272(33):20357-20363); chorismate synthase (Schmidt et al. (1993)J. Biol. Chem.268(36):27447-27457); and the light harvesting chlorophyll a/b binding protein (LHBP) (Lamppa et al. (1988)J. Biol. Chem.263:14996-14999). See also Von Heijne et al. (1991)Plant Mol. Biol. Rep.9:104-126; Clark et al. (1989)J. Biol. Chem.264:17544-17550; Della-Cioppa et al. (1987)Plant Physiol.84:965-968; Romer et al. (1993)Biochem. Biophys. Res. Commun.196:1414-1421; and Shah et al. (1986)Science233:478-481.
• Generally, the expression cassette will comprise a selectable marker gene for the selection of transformed cells. Selectable marker genes are utilized for the selection of transformed cells or tissues. Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin B phosphotransferase, as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). See generally, Yarranton (1992)Curr. Opin. Biotech.3:506-511; Christopherson et al. (1992)Proc. Natl. Acad. Sci. USA89:6314-6318; Yao et al. (1992)Cell71:63-72; Reznikoff (1992)Mol. Microbiol.6:2419-2422; Barkley et al. (1980) inThe Operon, pp. 177-220; Hu et al. (1987)Cell48:555-566; Brown et al. (1987)Cell49:603-612; Figge et al. (1988)Cell52:713-722; Deuschle et al. (1989)Proc. Natl. Acad. Aci. USA86:5400-5404; Fuerst et al. (1989)Proc. Natl. Acad. Sci. USA86:2549-2553; Deuschle et al. (1990)Science248:480-483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; Reines et al. (1993)Proc. Natl. Acad. Sci. USA90:1917-1921; Labow et al. (1990)Mol. Cell. Biol.10:3343-3356; Zambretti et al. (1992)Proc. Natl. Acad. Sci. USA89:3952-3956; Baim et al. (1991)Proc. Natl. Acad. Sci. USA88:5072-5076; Wyborski et al. (1991)Nucleic Acids Res.19:4647-4653; Hillenand-Wissman (1989)Topics Mol. Struc. Biol.10:143-162; Degenkolb et al. (1991)Antimicrob. Agents Chemother.35:1591-1595; Kleinschnidt et al. (1988)Biochemistry27:1094-1104; Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gossen et al. (1992)Proc. Natl. Acad. Sci. USA89:5547-5551; Oliva et al. (1992)Antimicrob. Agents Chemother.36:913-919; Hlavka et al. (1985)Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al. (1988)Nature334:721-724. Such disclosures are herein incorporated by reference.
• Other genes that could serve as selectable or scorable markers in the recovery of transgenic events but that might not be required in the final product would include, but are not limited to: GUS (β-glucoronidase), Jefferson (1987) Plant Mol. Biol. Rep. 5:387); fluorescent proteins, such as, GFP (green florescence protein), YFP (yello florescence protein), RFP (red florescence protein) and CYP (cyan florescence protein), WO 00/34321, WO 00/34526, WO 00/34323, WO 00/34322, WO 00/34318, WO 00/34319, WO 00/34320, WO 00/34325, WO 00/34326, WO 00/34324, Chalfie et al. (1994) Science 263:802; luciferase, Teeri et al. (1989) EMBO J. 8:343; and the maize genes encoding for anthocyanin production, Ludwig et al. (1990) Science 247:449.
• The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.
• The invention involves transforming host cells with the nucleotide constructs of the invention. Generally, the nucleotide construct will comprise a HGGT nucleotide and/or gamma-tocopherol methyltransferase sequence of the invention, either a full length sequence or functional fragment thereof, operably linked to a promoter that drives expression in the host cell of interest. Host cells include, but are not limited to: plant cells; animal cells; fungal cells, particularly yeast cells; and bacterial cells.
• The methods of the invention involve introducing a nucleotide construct into a plant. By “introducing” is intended presenting to the plant the nucleotide construct in such a manner that the construct gains access to the interior of a cell of the plant. The methods of the invention do not depend on a particular method for introducing a nucleotide construct to a plant, only that the nucleotide construct gains access to the interior of at least one cell of the plant. Methods for introducing nucleotide constructs into plants are known in the art including, but not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods.
• By “stable transformation” is intended that the nucleotide construct introduced into a plant integrates into the genome of the plant and is capable of being inherited by progeny thereof. By “transient transformation” is intended that a nucleotide construct introduced into a plant does not integrate into the genome of the plant.
• Transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing nucleotide sequences into plant cells and subsequent insertion into the plant genome include microinjection (Crossway et al. (1986)Biotechniques4:320-334), electroporation (Riggs et al. (1986)Proc. Natl. Acad. Sci. USA83:5602-5606, Agrobacterium-mediated transformation (Townsend et al., U.S. Pat. No. 5,563,055; Zhao et al., U.S. Pat. No. 5,981,840), direct gene transfer (Paszkowski et al. (1984)EMBO J.3:2717-2722), and ballistic particle acceleration (see, for example, Sanford et al., U.S. Pat. No. 4,945,050; Tomes et al., U.S. Pat. No. 5,879,918; Tomes et al., U.S. Pat. No. 5,886,244; Bidney et al., U.S. Pat. No. 5,932,782; Tomes et al. (1995) “Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment,” inPlant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); McCabe et al. (1988)Biotechnology6:923-926); and Lec1 transformation (PCT Publication No. 00/028058). Also see Weissinger et al. (1988)Ann. Rev. Genet.22:421-477; Sanford et al. (1987)Particulate Science and Technology5:27-37 (onion); Christou et al. (1988)Plant Physiol.87:671-674 (soybean); McCabe et al. (1988)Bio/Technology6:923-926 (soybean); Finer and McMullen (1991)In Vitro Cell Dev. Biol.27P:175-182 (soybean); Singh et al. (1998)Theor. Appl. Genet.96:319-324 (soybean); Datta et al. (1990)Biotechnology8:736-740 (rice); Klein et al. (1988)Proc. Natl. Acad. Sci. USA85:4305-4309 (maize); Klein et al. (1988)Biotechnology6:559-563 (maize); Tomes, U.S. Pat. No. 5,240,855; Buising et al., U.S. Pat. Nos. 5,322,783 and 5,324,646; Tomes et al. (1995) “Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment,” inPlant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg (Springer-Verlag, Berlin) (maize); Klein et al. (1988)Plant Physiol.91:440-444 (maize); Fromm et al. (1990)Biotechnology8:833-839 (maize); Hooykaas-Van Slogteren et al. (1984)Nature(London) 311:763-764; Bowen et al., U.S. Pat. No. 5,736,369 (cereals); Bytebier et al. (1987)Proc. Natl. Acad. Sci. USA84:5345-5349 (Liliaceae); De Wet et al. (1985) inThe Experimental Manipulation of Ovule Tissues, ed. Chapman et al. (Longman, N.Y.), pp. 197-209 (pollen); Kaeppler et al. (1990)Plant Cell Reports9:415-418 and Kaeppler et al. (1992)Theor. Appl. Genet.84:560-566 (whisker-mediated transformation); D'Halluin et al. (1992)Plant Cell4:1495-1505 (electroporation); Li et al. (1993)Plant Cell Reports12:250-255 and Christou and Ford (1995)Annals of Botany75:407-413 (rice); Osjoda et al. (1996)Nature Biotechnology14:745-750 (maize viaAgrobacterium tumefaciens); all of which are herein incorporated by reference.
• The nucleotide constructs of the invention may also be introduced into plants by contacting plants with a virus or viral nucleic acids. Generally, such methods involve incorporating a nucleotide construct of the invention within a viral DNA or RNA molecule. It is recognized that a HGGT and/or gamma-tocopherol methyltransferase of the invention may be initially synthesized as part of a viral polyprotein, which later may be processed by proteolysis in vivo or in vitro to produce the desired recombinant polypeptide. Further, it is recognized that promoters of the invention also encompass promoters utilized for transcription by viral RNA polymerases. Methods for introducing nucleotide constructs into plants and expressing a polypeptide encoded therein, involving viral DNA or RNA molecules, are known in the art. See, for example, U.S. Pat. Nos. 5,889,191, 5,889,190, 5,866,785, 5,589,367 and 5,316,931; herein incorporated by reference.
• Methods for transformation of chloroplasts are known in the art. See, for example, Svab et al. (1990)Proc. Natl. Acad. Sci. USA87:8526-8530; Svab and Maliga (1993)Proc. Natl. Acad. Sci. USA90:913-917; Svab and Maliga (1993)EMBO J.12:601-606. The method relies on particle gun delivery of DNA containing a selectable marker and targeting of the DNA to the plastid genome through homologous recombination. Additionally, plastid transformation can be accomplished by transactivation of a silent plastid-borne transgene by tissue-preferred expression of a nuclear-encoded and plastid-directed RNA polymerase. Such a system has been reported in McBride et al. (1994)Proc. Natl. Acad. Sci. USA91:7301-7305.
• The nucleic acids of interest to be targeted to the chloroplast may be optimized for expression in the chloroplast to account for differences in codon usage between the plant nucleus and this organelle. In this manner, the nucleic acids of interest may be synthesized using chloroplast-preferred codons. See, for example, U.S. Pat. No. 5,380,831, herein incorporated by reference.
• The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986)Plant Cell Reports5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved.
• As used herein, “transformed plants” include those plants directly transformed as provided herein, as well as plants that have the directly transformed plants in their pedigree and retain the change in genotype, such as the inclusion of the expression cassette, created by the original transformation.
• The present invention may be used for transformation of any plant species, including, but not limited to, maize (Zea mays),Brassicasp. (e.g.,B. napus, B. rapa, B. juncea), particularly thoseBrassicaspecies useful as sources of seed oil, alfalfa (Medicago sativa), rice (Oryza sativa), rye (Secale cereale), sorghum (Sorghum bicolor, Sorghum vulgare), millet (e.g., pearl millet (Pennisetum glaucum), proso millet (Panicum miliaceum), foxtail millet (Setaria italica), finger millet (Eleusine coracana)), sunflower (Helianthus annuus), safflower (Carthamus tinctorius), wheat (Triticum aestivum), soybean (Glycine max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum), peanuts (Arachis hypogaea), cotton (Gossypium barbadense, Gossypium hirsutum), sweet potato (Ipomoea batatus), cassava (Manihot esculenta), coffee (Coffeaspp.), coconut (Cocos nucifera), pineapple (Ananas comosus), citrus trees (Citrusspp.), cocoa (Theobroma cacao), tea (Camellia sinensis), banana (Musaspp.), avocado (Persea americana), fig (Ficus casica), guava (Psidium guajava), mango (Mangifera indica), olive (Olea europaea), papaya (Carica papaya), cashew (Anacardium occidentale),macadamia(Macadamia integrifolia), almond (Prunus amygdalus), sugar beets (Beta vulgaris), sugarcane (Saccharumspp.), oats, barley, vegetables, ornamentals, and conifers.
• Vegetables include tomatoes (Lycopersicon esculentum), lettuce (e.g.,Lactuca sativa), green beans (Phaseolus vulgaris), lima beans (Phaseolus limensis), peas (Lathyrusspp.), and members of the genusCucumissuch as cucumber (C. sativus), cantaloupe (C. cantalupensis), and musk melon (C. melo). Ornamentals include azalea (Rhododendronspp.), hydrangea (Macrophylla hydrangea), hibiscus (Hibiscus rosasanensis), roses (Rosaspp.), tulips (Tulipaspp.), daffodils (Narcissusspp.), petunias (Petunia hybrida), carnation (Dianthus caryophyllus), poinsettia (Euphorbia pulcherrima), and chrysanthemum. Conifers that may be employed in practicing the present invention include, for example, pines such as loblolly pine (Pinus taeda), slash pine (Pinus elliotii), ponderosa pine (Pinus ponderosa), lodgepole pine (Pinus contorta), and Monterey pine (Pinus radiata); Douglas-fir (Pseudotsuga menziesii); Western hemlock (Tsuga canadensis); Sitka spruce (Picea glauca); redwood (Sequoia sempervirens); true firs such as silver fir (Abies amabilis) and balsam fir (Abies balsamea); and cedars such as Western red cedar (Thuja plicata) and Alaska yellow-cedar (Chamaecyparis nootkatensis). Preferably, plants of the present invention are crop plants (for example, maize, alfalfa, sunflower,Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, barley, rice, sorghum, rye, millet, tobacco, etc.), more preferably cereal plants, yet more preferably maize, wheat, barley, rice, sorghum, rye and millet plants.
• In some embodiments, the activity of a gene of the invention is reduced or eliminated by transforming a plant cell with an expression cassette expressing a polynucleotide that inhibits the expression of a target gene. The polynucleotide may inhibit the expression of one or more target genes directly, by preventing translation of the target gene messenger RNA, or indirectly, by encoding a polypeptide that inhibits the transcription or translation of a gene encoding the target gene. Methods for inhibiting or eliminating the expression of a gene in a plant are well known in the art, and any such method may be used in the present invention to inhibit the expression of one or more plant genes, such as, HGGT and/or gamma-tocoperol methyltransferase.
• In accordance with the present invention, the expression of a target gene protein is inhibited if the protein level of the target gene is statistically lower than the protein level of the same target gene in a plant that has not been genetically modified or mutagenized to inhibit the expression of that target gene. In particular embodiments of the invention, the protein level of the target gene in a modified plant according to the invention is less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% of the protein level of the same target gene in a plant that is not a mutant or that has not been genetically modified to inhibit the expression of that target gene. The expression level of the target gene may be measured directly, for example, by assaying for the level of target gene expressed in the maize cell or plant, or indirectly, for example, by measuring the activity of the target gene enzyme in the maize cell or plant. The activity of a target gene protein is “eliminated” according to the invention when it is not detectable by at least one assay method described elsewhere herein.
• Many methods may be used to reduce or eliminate the activity of a target gene. More than one method may be used to reduce the activity of a single target gene. In addition, combinations of methods may be employed to reduce or eliminate the activity of two or more different target genes. Non-limiting examples of methods of reducing or eliminating the expression of a plant target are given below.
• Many techniques for gene silencing are well known to one of skill in the art, including but not limited to knock-outs, such as, by insertion of a transposable element such as mu (Vicki Chandler,The Maize Handbookch. 118 (Springer-Verlag 1994)), other genetic elements such as a FRT, Lox or other site specific integration site, alteration of the target gene by homologous recombination (Bolon, B. Basic Clin. Pharmacol. Toxicol. 95:4, 12, 154-61 (2004); Matsuda and Alba, A., Methods Mol. Bio. 259:379-90 (2004); Forlino, et. al., J. Biol. Chem. 274:53, 37923-30 (1999), antisense technology (see, e.g., Sheehy et al. (1988)PNASUSA 85:8805-8809; and U.S. Pat. Nos. 5,107,065; 5,453, 566; and 5,759,829; U.S. Patent Publication No. 20020048814); sense suppression (e.g., U.S. Pat. No. 5,942,657; Flavell et al. (1994)Proc. Natl. Acad. Sci. USA91: 3490-3496; Jorgensen et al. (1996)Plant Mol. Biol.31: 957-973; Johansen and Carrington (2001)Plant Physiol.126: 930-938; Broin et al. (2002)Plant Cell14: 1417-1432; Stoutjesdijk et al (2002)Plant Physiol.129: 1723-1731; Yu et al., (2003)Phytochemistry63: 753-763; and U.S. Pat. Nos. 5,034,323, 5,283,184, and 5,942,657; U.S. Patent Publication No. 20020048814); RNA interference (Napoli et al. (1990)Plant Cell2:279-289; U.S. Pat. No. 5,034,323; Sharp (1999)Genes Dev.13:139-141; Zamore et al. (2000)Cell101:25-33; and Montgomery et al. (1998)PNASUSA 95:15502-15507), virus-induced gene silencing (Burton, et al. (2000)Plant Cell12:691-705; and Baulcombe (1999)Curr. Op. Plant Bio.2:109-113); target-RNA-specific ribozymes (Haseloff et al. (1988)Nature334: 585-591, U.S. Pat. No. 4,987,071); hairpin structures (Smith et al. (2000)Nature407:319-320; Waterhouse et al. (1998)Proc. Natl. Acad. Sci. USA95: 13959-13964, Liu et al. (2002)Plant Physiol.129: 1732-1743, Waterhouse and Helliwell (2003)Nat. Rev. Genet.4:29-38; Chuang and Meyerowitz (2000)Proc. Natl. Acad. Sci. USA97: 4985-4990; Stoutjesdijk et al. (2002)Plant Physiol.129: 1723-1731; Panstruga et al. (2003)Mol. Biol. Rep.30: 135-140; Smith et al. (2000)Nature407: 319-320; Smith et al. (2000)Nature407:319-320; Wesley et al. (2001)Plant J.27: 581-590; Wang and Waterhouse (2001)Curr. Opin. Plant Biol.5: 146-150; Waterhouse and Helliwell (2003)Nat. Rev. Genet.4: 29-38; Helliwell and Waterhouse (2003)Methods30: 289-295; Pandolfini et al.BMC Biotechnology3: 7; U.S. Patent Publication No. 20030180945; U.S. Patent Publication No. 20030175965; WO 99/49029; WO 99/53050; WO 99/61631; and WO 00/49035); transcriptional gene silencing (TGS) (Aufsatz et al. (2002)Proc. Nat'l. Acad. Sci.99 (Suppl. 4):16499-16506; Mette et al. (2000)EMBO J.19(19):5194-5201; microRNA (Aukerman & Sakai (2003) Plant Cell 15:2730-2741); ribozymes (Steinecke et al. (1992)EMBO J.11:1525; and Perriman et al. (1993)Antisense Res. Dev.3:253); oligonucleotide mediated targeted modification (e.g., WO 03/076574 and WO 99/25853); Zn-finger targeted molecules (e.g., WO 01/52620; WO 03/048345; and WO 00/42219); methods of using amplicons (Angell and Baulcombe (1997)EMBO J.16: 3675-3684, Angell and Baulcombe (1999)Plant J.20: 357-362, and U.S. Pat. No. 6,646,805); polynucleotides that encode an antibody that binds to protein of interest (Conrad and Sonnewald (2003)Nature Biotech.21: 35-36); transposon tagging (Maes et al. (1999)Trends Plant Sci.4: 90-96; Dharmapuri and Sonti (1999)FEMS Microbiol. Lett.179: 53-59; Meissner et al. (2000)Plant J.22: 265-274; Phogat et al. (2000)J. Biosci.25: 57-63; Walbot (2000)Curr. Opin. Plant Biol.2: 103-107; Gai et al. (2000)Nucleic Acids Res.28: 94-96; Fitzmaurice et al. (1999)Genetics153: 1919-1928; the TUSC process for selecting Mu insertions in selected genes (Bensen et al. (1995)Plant Cell17: 75-84; Mena et al., (1996)Science274: 1537-1540; and U.S. Pat. No. 5,962,764); other forms of mutagenesis, such as ethyl methanesulfonate-induced mutagenesis, deletion mutagenesis, and fast neutron deletion mutagenesis used in a reverse genetics sense (with PCR) to identify plant lines in which the endogenous gene has been deleted (Ohshima et al. (1998)Virology243: 472-481; Okubara et al., (1994)Genetics137: 867-874; and Quesada et al., (2000)Genetics154: 421-436; TILLING (Targeting Induced Local Lesions In Genomes) (McCallum et al. (2000)Nat. Biotechnol.18: 455-457) and other methods or combinations of the above methods known to those of skill in the art. Each reference is herein incorporated by reference
• An expression cassette is designed to reduce activity of the target gene may express an RNA molecule corresponding to all or part of a messenger RNA encoding a target gene in the sense or antisense orientation or a combination of both sense and antisense. Overexpression of the RNA molecule can result in reduced expression of the native gene. Accordingly, multiple plant lines transformed with the sense suppression expression cassette are screened to identify those that show the greatest inhibition of the target gene's expression.
• The polynucleotide used for target gene suppression may correspond to all or part of the sequence encoding the target gene, all or part of the 5′ and/or 3′ untranslated region of a target gene transcript, or all or part of both the coding region and the untranslated regions of a transcript encoding of the target gene or all or part of the promoter sequence responsible for expression of the target gene. A polynucleotide used for sense suppression or other gene silencing methods may share 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 85%, 80%, or less sequence identity with the target sequence. When portions of the polynucleotides are used to disrupt the expression of the target gene, generally, sequences of at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, 450, 500, 550, 600, 650, 700, 750, 800, or 900 nucleotides or 1 kb or greater may be used.
• The following examples are presented by way of illustration, not by way of limitation.
EXPERIMENTAL
• The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration, not by way of limitation. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.
EXAMPLE 1Alpha- and Beta-Tocotrienol Production inArabidopsis thalianaby Transgenic Expression of Barley HGGT and Soybean Gamma-Tocopherol Methyltransferase
• The cDNA for barley homogentisate geranylgeranyl transferase (HGGT) (bdl2c.pk006.o2; SEQ ID NO:2) and soybean gamma-tocopherol methyltransferase (sah1c.pk004.g2; SEQ ID NO:12) were expressed inArabidopsis thalianato demonstrate the feasability of these cDNA for alpha and beta-tocotrienol production in transgenic plants.
• A transformation vector was constructed using standard molecular tools that expressed the barley HGGT gene under the control of the β-conglycinin promoter of soybean (Beachy et al.,EMBO J.4:3047-3053 (1985)) and the soybean gamma-tocopherol methyltransferase gene under the control of the Kti promoter (Kunitz Trypsin Inhibitor, Jofuku et. al., (1989) Plant Cell 1:1079-1093).
• The 1.1 kb DNA fragment containing the soybean gamma-tocopherol methyltransferase gene was excised from SC1 (see Example 3) using the restriction enzyme NotI, and ligated, in the sense orientation behind the Kti promoter, to DNA of KS126 (PCT Publication No. WO 04/071467) linearized with the restriction enzyme NotI to give KS308 (SEQ ID NO:41).
• The 3.1 kb DNA fragment containing β-conglycinin promoter, HGGT gene, and phaseolin terminator was excised from SC38 (see Example 3) using the restriction enzyme AscI, the ends were blunted with the large fragment of DNA polymerase I, and ligated to DNA of KS178 (construction described below) to give KS270 (SEQ ID NO:42). KS178 had previously been linearized with the restriction enzyme PacI followed by filling in of 3′ overhangs with the large fragment of DNA polymerase I.
• KS178 was constructed as follows. The 4.0 kb DNA fragment containing the SAMS/ALS/ALS3′ cassette, was excised from pZSL13LeuB (PCT Publication No. WO 04/071467) using the restriction enzymes PstI and SmaI, the ends were blunted with the large fragment of DNA polymerase I, and ligated to DNA of KS102 (PCT Publication No. WO 04/071467) linearized with the restriction enzyme BamHI, to give KS178. Prior to ligation the ends of the linearized KS102 vector were blunted with the large fragment of DNA polymerase I.
• The 3.4 kb DNA fragment containing the gamma-tocopherol methyltransferase expression cassette was excised from KS308 using the restriction enzyme AscI, the ends were blunted with the large fragment of DNA polymerase I, and ligated to DNA of pBluescript II KS-(Stratagene) linearized with the restriction enzyme SmaI. The resulting vector was linearized with the restriction enzyme SnaBI, and ligated to the 3.0 kb DNA fragment containing the HGGT expression cassette removed from KS270 using the restriction enzymes PacI and BamHI to give KS318. Prior to ligation the ends of this fragment were blunted with the large fragment of DNA polymerase I. The 6.4 kb DNA fragment containing the HGGT and gamma-tocopherol methyltransferase expression cassettes was excised from KS318 using the restriction enzyme SalI, and ligated to DNA of theAgrobacterium tumefaciensbinary vector pZBL120, linearized with SalI, to give KS319. The T-DNA of the plant transformation vector KS319 is set forth as SEQ ID NO:43.
• Applicants note that the binary vector pZBL120 is identical to the pZBL1 binary vector (American Type Culture Collection Accession No. 209128) described in U.S. Pat. No. 5,968,793, except the NOS promoter was replaced with a 963 bp 35S promoter (NCBI Accession No. V00141; also known as NCBI General Indentifier No. 58821) from nucleotide 6494 to 7456 in the Nos/P-nptll-OCS 3′ gene. The new 35S promoter-nptll-OCS 3′ gene serves as a kanamycin (Kan) resistance plant selection marker in pZBL120.
• Generation and Analysis of Transgenic Arabidospis Lines:
• Plasmid DNA of KS319 was introduced intoAgrobacterium tumefaciensNTL4 (Luo et al,Molecular Plant-Microbe Interactions(2001) 14(1):98-103) by electroporation. Briefly, 1 μg plasmid DNA was mixed with 100 μL of electro-competent cells on ice. The cell suspension was transferred to a 100 μL electro oration curette (1 mm gap width) and electro orated using a BIORAD electro orator set to 1 kV, 400Ω and 25 μF. Cells were transferred to 1 mL LB medium and incubated for 2 h at 30° C. Cells were plated onto LB medium containing 50 μg/mL kanamycin. Plates were incubated at 30° C. for 60 h. Recombinantagrobacteriumcultures (500 mL LB, 50 μg/mL kanamycin) were inoculated from single colonies of transformedagrobacteriumcells and grown at 30° C. for 60 h. Cells were harvested by centrifugation (5000×g, 10 min) and resuspended in 1 L of 5% (W/V) sucrose containing 0.05% (V/V) Silwet.Arabidopsisplants were grown in soil at a density of 30 plants per 100 cm²pot in metromix 360 soil mixture for 4 weeks (22° C., 16 h light/8 h dark, 100 μE m⁻²s⁻¹). Plants were repeatedly dipped into theagrobacteriumsuspension harboring the binary vector KS319 and kept in a dark, high humidity environment for 24 h. Plants were grown for three to four weeks under standard plant growth conditions described above and plant material was harvested and dried for one week at ambient temperatures in paper bags. Seeds were harvested using a 0.425 mm mesh brass sieve.
• CleanedArabidopsisseeds (2 grams, corresponding to about 100,000 seeds) were sterilized by washes in 45 mL of 80% ethanol, 0.01% triton X-100, followed by 45 mL of 30% (V/V) household bleach in water, 0.01% triton X-100 and finally by repeated rinsing in sterile water. Aliquots of 20,000 seeds were transferred to square plates (20×20 cm) containing 150 mL of sterile plant growth medium comprised of 0.5×MS salts, 1.0% (W/V) sucrose, 0.05 MES/KOH (pH 5.8), 200 μg/mL timentin, and 50 μg/mL kanamycin solidified with 10 g/L agar. Homogeneous dispersion of the seed on the medium was facilitated by mixing the aqueous seed suspension with an equal volume of melted plant growth medium. Plates were incubated under standard growth conditions for ten days. Kanamycin-resistant seedlings were transferred to plant growth medium without selective agent and grown to maturity.
• A total of 137 transgenic lines were generated and subjected to HPLC analysis: 5 mg crushed seed were extracted at ambient temperature in 200 μL of heptane. Tocopherols and tocotrienols were quantitated by HPLC as described in Example 3. The highest total tocotrienol content was 2,800 ppm. The highest alpha-tocotrienol content was 400 ppm. In these events, 25% of all tocopherols and tocotrienols comprised of alpha-tocotrienol.
• Two events, #58 and #135 were advanced to transgene homozygousity by repeated selfing. T2 seed of both events contained 25% of kanamycin-sensitive seed indicating that both events contained transgene insertion at a single genetic locus. Bulk seed were produced from T3 seed that no longer segregated kanamycin-sensitive progeny. 50 mg of T4 seed material was extracted in 1 mL of heptane. Tocopherol and tocotrienol were quantitated by HPLC and these results are found in Table 3. As discussed below, event #58 expressed HGGT and gamma-tocopherol methyltransferase genes. Event #135 expressed only HGGT.

  TABLE 3
  Tocol Composition (% of total tocols) of Homozygous
  T4 Seed Material of TransgenicArabidopsisLines

  		alpha-	beta-	gamma-	delta-
  line		tocopherol	tocopherol	tocopherol	tocopherol	tocopherol
  wild-	ppm	6	0	396	9	411
  type	%		2	0	96	2
  #135	ppm	25	4	326	104	455
  	%	1	0	12	4
  #58	ppm	308	58	98	30	495
  	%	15	3	5	1
  		alpha-	beta-	gamma-	delta
  		tocotrienol	tocotrienol	tocotrienol	tocotrienol	tocotrienol
  wild-	ppm	0	0	0	0	0
  type	%	0	0	0	0
  #135	ppm	13	0	1754	590	2358
  	%	0	0	62	21
  #58	ppm	419	47	876	273	1615
  	%	20	2	42	13

• Table 3 indicates that event #135 apparently only expresses the barley HGGT gene. The seed tocotrienol profile of event #135 resembles that of leaves of transgenicArabidopsisplants over-expressing the barley HGGT gene. The leaf profile is dominated by gamma-tocotrienol with alpha-tocotrienol comprising less than 3% of the total tocotrienol fraction (see PCT Publication No. WO 03/082899; U.S. Application No. 2004/0034886; Cahoon et al. (2003)Nat. Biotechnol.21:1082-1087). Applicants note that in line #135 only trace levels of alpha-tocotrienol are detected. Hence, there is very little endogenous enzyme activity present inArabidopsisseed that can convert gamma-tocotrienol to alpha-tocotrienol.
• In contrast to the above, the co-expression of the soybean gamma-tocopherol methyltransferase gene with the HGGT gene in event #58 leads to significant accumulation of alpha-tocotrienol with levels of 419 ppm. The oil content of heptane extracts was measured using sodium methoxide derivatization followed by GC analysis (see below). Using this analysis, it was determined that the seed oil of event #58 contained 1,200 ppm alpha-tocotrienol. The alpha-tocotrienol of event #58 makes up about 20% of the total tocopherols and tocotrienols. About 30% of gamma-tocotrienol is converted to alpha-tocotrienol. Applicants note that expression of the gamma-tocopherol methyltransferase gene may be low, because a heterologous promoter was used. Even higher levels of alpha-tocotrienol will very likely be observed if the gamma-tocopherol methyltransferase gene is expressed under control of an endogenous seed-preferred promoter. Nevertheless, theArabidopsisdata has demonstrated that the soybean gamma-tocopherol methyltransferase gene is an efficient enzyme catalyst for methylation of tocotrienols for the production of alpha- and beta-tocotrienol.
• One skilled in the art understands that the homogentisate geranylgeranyl transferases (HGGT) and gamma-tocopherol methyltransferases found in Table 1 and Table 2, respectively, may also be expressed inArabidopsis thalianato demonstrate the feasability of using these cDNA to increase alpha and beta-tocotrienol production in transgenic plants.
• GC/MS Analysis to Confirm Identity of Tocopherols and Tocotrienols:
• Total tocol analysis was performed on an Agilent 6890 gas chromatograph in conjunction with Agilent 5973 Mass Selective Detector (MSD). Four μL samples of heptane extracts ofArabidopsisseeds of lines #58 and #135 were injected into a split/splitless injector (2:1 split ratio) held at 300° C. Chromatographic separation was performed on a 30 m×250 μm (ID)×0.25 μm (film thickness) Agilent DB5MS column using helium gas as the carrier (39 cm/sec linear velocity). The oven temperature profile was as follows: 260° C., hold 4 min; 2° C. ramp to 340° C., hold for 12 min. Compounds eluting from the column were directed into the MSD though a heated (325° C.) transfer line and ionized (70 eV). The MSD was tuned using the standard tune protocol and was run in Scan mode (10-500 mass range). Data was analyzed using ChemStation (Agilent) and AMDIS version 2.1 (National Institute of Standards and Technology; NIST).
• Compound identity was confirmed by comparing compound elution times with those of authentic samples and by mass spectral comparisons with an electronic database (version 2.0, NIST). The database contained entries for alpha-, beta-, gamma- and delta-tocopherols, as well as the internal standard (alpha-tocopherol acetate). Library entries were not available for any of the tocotrienols. The identity of these compounds was therefore confirmed by comparison of the chromatographic elution and by visual comparison of the mass-spectrum with those of authentic standards run under the same chromatographic conditions.
EXAMPLE 2Production of Tocotrienols in Transgenic Soybean Lines: Molecular Stack of Barley HGGT and Soybean Gamma-Tocopherol Methyltransferase
• To demonstrate the ability to produce increased levels of alpha- and beta-tocotrienols in transgenic soybean lines, the barley HGGT cDNA (bdl2c.pk006.o2; SEQ ID NO:2) and soybean gamma-tocopherol methyltransferase (sah1c.pk004.g2; SEQ ID NO:12) were used in a molecular stack (progeny with both transgene-related traits).
• Transgenic soybean lines were generated with plasmid DNA of KS270 and KS308, see Example 1, using particle bombardment of embryogenic callus.
• KS270 provides the barley HGGT gene under control of 617 bp of the soybean β-conglycinin promoter. The polyadenylation signal for the HGGT transcript is derived from the terminator of the phaseolin gene (from the beanPhaseolus vulgaris; Doyle et al. (1986)J. Biol. Chem.261:9228-9238). The plasmid also contains the cDNA of a sulfonylurea-resistant variant of the soybean ALS gene that is under control of 1217 bp of the SAMS promoter. The polyadenylation signal for the HGGT transcript is derived from the terminator of the soybean ALS gene.
• KS308 provides the gamma-tocopherol methyltransferase gene from soybean under the control of 2090 bp of the soybean Kti promoter. The polyadeylation signal for the gamma-tocopherol methyltransferase transcript is derived from the terminator of the Kti gene. KS308 also provides a hygromycin B phosphotransferase (HPT) resistance gene (Gritz et al. (1983)Gene25:179-188) that is under control of 1408 bp of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985)Nature313:810-812). The polyadenylation signal for the hygromycin resistance gene is derived from the terminator of nopaline synthase gene from the T-DNA of the Ti plasmid ofAgrobacterium tumefaciens.
• Soybean embryogenic suspension cultures were transformed with DNA plasmids KS270 in conjunction with KS308 by the method of particle gun bombardment (Klein et al. (1987)Nature(London) 327:70-73, U.S. Pat. No. 4,945,050) using a BIORAD Biolistic PDS1000/He instrument. The following stock solutions and media were used for transformation and regeneration of soybean plants:
• Stock Solutions:
• Sulfate 100×Stock: 37.0 g MgSO₄.7H₂O, 1.69 g MnSO₄.H₂O, 0.86 g ZnSO₄.7H₂O, 0.0025 g CuSO₄.5H₂O
• Halides 100×Stock: 30.0 g CaCl₂.2H₂O, 0.083 g KI, 0.0025 g CoCl₂.6H₂O
• P, B, Mo 100×Stock: 18.5 g KH₂PO₄, 0.62 g H₃BO₃, 0.025 g Na₂MoO₄.2H₂O
• Fe EDTA 100×Stock: 3.724 g Na₂EDTA, 2.784 g FeSO₄.7H₂O
• 2,4-D Stock: 10 mg/mL
• Vitamin B5 1000×Stock: 10.0 g myo-inositol, 0.10 g nicotinic acid, 0.10 g pyridoxine HCl, 1 g thiamine.
• Media (per Liter):
• SB196: 10 mL of each of the above stock solutions, 1 mL B5 Vitamin stock, 0.463 g (NH₄)₂SO₄, 2.83 g KNO₃, 1mL 2,4-D stock, 1 g asparagine, 10 g Sucrose, pH 5.7
• SB103: 1 pk. Murashige & Skoog salts mixture, 1 mL B5 Vitamin stock, 750 mg MgCl₂hexahydrate, 60 g maltose, 2 g gelrite, pH 5.7.
• SB166: SB103 supplemented with 5 g per liter activated charcoal.
• SB71-4: Gamborg's B5 salts, 1 mL B5 vitamin stock, 30 g sucrose, 5 g TC agar, pH 5.7.
• To prepare tissue for transformation, soybean embryogenic suspension cultures were maintained in 35 mL liquid medium (SB196) on a rotary shaker (150 rpm) at 28° C. with fluorescent lights providing a 16 hour day/8 hour night cycle. Cultures were subcultured every 2 weeks by inoculating approximately 35 mg of tissue into 35 mL of fresh liquid media.
• In particle gun bombardment procedures it is possible to use purified 1) entire plasmid DNA or, 2) DNA fragments containing only the recombinant DNA expression cassette(s) of interest. For every seventeen bombardment transformations, 85 μL of suspension is prepared containing 1 to 90 picograms (pg) of plasmid DNA per base pair of each DNA plasmid. Both recombinant DNA plasmids were co-precipitated onto gold particles as follows. The DNAs in suspension were added to 50 μL of a 20-60 mg/mL 0.6 μm gold particle suspension and then combined with 50 μL CaCl₂(2.5 M) and 20 μL spermidine (0.1 M). The mixture was vortexed for 5 seconds, spun in a microfuge for 5 seconds, and the supernatant removed. The DNA-coated particles were then washed once with 150 μL of 100% ethanol, vortexed and spun in a microfuge again, then resuspended in 85 μL of anhydrous ethanol. Five μL of the DNA-coated gold particles were then loaded on each macrocarrier disk.
• Approximately 150 to 250 mg of two-week-old suspension culture was placed in an empty 60 mm×15 mm petri plate and the residual liquid removed from the tissue using a pipette. The tissue was placed about 3.5 inches away from the retaining screen and each plate of tissue was bombarded once. Membrane rupture pressure was set at 650 psi and the chamber was evacuated to −28 inches of Hg. Three plates were bombarded, and, following bombardment, the tissue from each plate was divided between two flasks, placed back into liquid media, and cultured as described above.
• Seven days after bombardment, the liquid medium was exchanged with fresh SB196 medium supplemented with 30-50 mg/L hygromycin. The selective medium was subsequently refreshed weekly or biweekly. Seven weeks post-bombardment, bright green, transformed tissue was observed growing from untransformed, chlorotic or necrotic embryogenic clusters. Isolated green tissue was removed and inoculated into individual wells in six-well culture dishes to generate new, clonally-propagated, transformed embryogenic suspension cultures. Thus, each new line was treated as independent transformation event in an individual well. These suspensions can then be maintained as suspensions of embryos clustered in an immature developmental stage through subculture or they can be regenerated into whole plants by maturation and germination of individual somatic embryos.
• After two weeks in individual cell wells, transformed embryogenic clusters were removed from liquid culture and placed on solidified medium (SB166) containing no hormones or antibiotics for one week. Embryos were cultured for at 26° C. with mixed fluorescent and incandescent lights on a 16 hour day/8 hour night schedule. After one week, the cultures were then transferred to SB103 medium and maintained in the same growth conditions for 3 additional weeks.
• Somatic embryos became suitable for germination after 4 weeks and were then removed from the maturation medium and dried in empty petri dishes for 1 to 5 days. The dried embryos were then planted in SB71-4 medium where they were allowed to germinate under the same light and temperature conditions as described above. Germinated embryos were transferred to sterile soil and grown to maturity for seed production.
• A total of fourteen events were created by co-transformation with KS270 and KS308 plasmids. Tocol composition of T1 seed was assayed as follows. A seed chip (approximately 5-15 mg of tissue) was obtained from the cotyledon tissue of the seed. The chip was extracted with 100 μL of heptane for 2 hours. Tocopherol and tocotrienol was quantitated by HPLC analysis as described in Example 3.
• A total of 14 events were generated and analyzed. Seed from five events contained significant levels of tocotrienol. Three of these also contained significant levels (>150 ppm) of alpha- and beta-tocotrienol. One event did not show conversion of gamma- to alpha-tocotrienol and one event did only exhibit low levels of gamma-tocopherol methyltransferase activity (20-150 ppm alpha-tocotrienol). One event 4060.2.5.1 was selected for further work. For event 4060.2.5.1, seven out of ten T1 seed showed the transgenic trait, indicating that these events likely had a single or multiple transgenic insertion at a single genetic locus. Positive-positive T1 seed were planted and T2 seed were selected from individual plants. A total of forty-eight T2 seed was analyzed by HPLC and the results can be found in Table 4.

  TABLE 4
  Tocol Composition (% of total tocopherols (tocph.) and tocotrienols (toct.))
  for T2 Progeny of Event 4060.2.5.1

  	alpha-	beta-	gamma-	delta-	alpha-	beta-	gamma-	delta-	tocph.	tact.
  No.	tocph.	tocph.	tocph.	tocph.	toct.	toct.	toct.	toct.	(ppm)	(ppm)

  1	8	4	0	0	31	24	12	20	406	2786
  2	9	5	0	0	31	22	15	19	474	3100
  3	8	4	0	0	30	24	13	21	453	3172
  4	9	4	0	0	30	23	14	20	471	2922
  5	7	4	0	0	30	24	13	21	389	3059
  6	9	5	0	0	29	22	13	22	479	3046
  7	9	5	0	0	29	23	12	22	434	2596
  8	9	5	0	0	29	22	13	22	454	2693
  9	9	5	0	0	28	22	13	22	442	2595
  10	10	5	0	0	28	22	13	22	487	2686
  11	8	5	0	0	28	22	15	21	292	1846
  12	10	5	0	0	27	22	12	23	401	2120
  13	10	5	0	0	27	23	12	23	384	2164
  14	10	5	0	0	27	19	17	23	424	2481
  15	8	3	0	0	26	14	26	22	382	2912
  16	8	5	0	0	26	22	14	26	468	3128
  17	8	5	0	0	26	22	14	26	399	2692
  18	9	5	0	0	25	21	14	25	477	2906
  19	7	5	0	0	25	23	13	26	365	2580
  20	7	5	0	0	25	21	14	27	405	2826
  21	7	5	0	0	25	22	14	27	442	3138
  22	11	5	0	0	24	16	19	24	408	2084
  23	8	6	0	0	24	22	14	27	435	2818
  24	7	5	0	0	24	20	15	29	411	2947
  25	9	6	0	0	24	21	13	27	412	2340
  26	9	6	0	0	24	20	15	27	453	2624
  27	9	6	0	0	23	21	14	27	392	2315
  28	9	6	0	0	23	20	14	28	443	2415
  29	8	2	1	0	22	10	36	21	460	3873
  30	7	5	0	0	22	21	14	30	386	2723
  31	9	5	0	0	22	18	17	30	435	2718
  32	16	1	73	10	0	0	0	0	383	0
  33	51	2	45	2	0	0	0	0	368	0
  34	35	2	59	4	0	0	0	0	362	0
  35	20	1	69	10	0	0	0	0	353	0
  36	36	2	56	5	0	0	0	0	325	0
  37	18	2	71	10	0	0	0	0	357	0
  38	35	3	58	5	0	0	0	0	307	0
  39	13	2	74	11	0	0	0	0	302	0
  40	25	2	64	9	0	0	0	0	353	0
  41	18	1	71	10	0	0	0	0	328	0
  42	25	2	64	9	0	0	0	0	353	0
  43	17	2	70	11	0	0	0	0	384	0
  44	14	1	73	12	0	0	0	0	337	0
  45	20	1	70	8	0	0	0	0	344	0
  46	16	1	73	10	0	0	0	0	335	0
  47	16	1	74	10	0	0	0	0	328	0
  48	18	1	71	8	0	0	0	2	354	0

• The T2 seed were generated through selfing of a transgenic line that was heterzogous for a single dominant transgenic trait. Accordingly, one would expect to detect 25% (12/48) non-transgenic segregants. Applicants observed 35% (17/48) non-transgenic segregants (see numbers 32-48). Seeds numbers 1 to 31 are transgenic segregants.
• T2 progeny with both transgene-related traits were found to contain at least 590 ppm and as much as 1,099 ppm alpha-tocotrienol and at least 401 ppm and as much as 868 ppm beta-tocotrienol. In these T2 lines, alpha-tocotrienol constituted at least 22% and up to 31%, and integers in between, of the total tocopherol and tocotrienol fraction. Oil content of the heptane extracts was determined by derivatization with sodium methoxide followed by GC analysis. Oil could be calculated from that tocotrienol concentrations expressed as ppm. T2 progeny with both transgene-related traits contained an oil with at least 2,618 ppm and as much as 4,891 alpha-tocotrienol and at least 1,732 ppm and as much as 3,804 ppm beta-tocotrienol. Applicants also tested for a possible negative effect of the high alpha- and beta-tocotrienol content on seed weight. To this end, seed weight of the forty-eight T2 seed was plotted against alpha-tocotrienol content. No correlation between seed weight and alpha-tocotrienol content could be detected. Moreover, no unusual seed phenotypes related to seed shape, coloration or germination behaviour were observed in seed with the high alpha- and beta-tocotrienol trait.
• One skilled in the art understands that the homogentisate geranylgeranyl transferases (HGGT) and gamma-tocopherol methyltransferases found in Table 1 and Table 2, respectively, may also be expressed in soybean to demonstrate the feasability of these cDNA for alpha- and beta-tocotrienol production in transgenic plants.
• In summary, gamma-tocopherol methyltransferase enzyme from soybean can efficiently use tocotrienol substrates, for example, by the foregoing method to generate a seed or an extracted oil with high levels of alpha- and beta-tocotrienol. The alpha-tocotrienol content of soybeans over-expressing barley HGGT and the soybean gamma-tocopherol methyltransferase gene exceeds that of any non-transgenic seed or oil described previously by at least one order of magnitude (Packer et al. (2001)J. Nutr.131:369S-373S; Bertoli et al. (1998)JAOCS75:1037-1040; PCT Publication No. WO 00/072862). These results further demonstrate the ability to produce alpha- and beta-tocotrienols in a crop plant that does not normally accumulate these antioxidant molecules through the transgenic expression of nucleic acid fragments encoding HGGT and gamma-tocopherol methyltransferase polypeptides.
EXAMPLE 3Production of Tocotrienols in Somatic Soybean Embryos and Transgenic Soybean Lines: Genetic Crossing of Barly HGGT and Soybean gamma-Tocopherol Methyltransferase
• To demonstrate the ability to produce increased levels of alpha- and beta-tocotrienols in somatic soybean embryos and transgenic soybean lines, the barley HGGT cDNA (bdl2c.pk006.o2; SEQ ID NO:2) and soybean gamma-tocopherol methyltransferase (sah1c.pk004.g2; SEQ ID NO:12) were used in a genetic stack (progeny with both transgene-related traits produced by crossing).
• Somatic soybean embryos have been used as model for the prediction of transgenic phenotypes in soybean seeds (Kinney, A. J. (1996)J. Food Lipids3:273-292). Somatic soybean embryos and seeds are enriched in tocopherols, but contain little or no tocotrienols (Coughlan, unpublished result; The Lipid Handbook, 2nd Edition, Gunstone, F. D., et al., Eds., Chapman and Hall, London, 1994, pp. 129-131).
• Plasmid DNA from clone sah1c.pk004.g2 was used as a template to prepare a NotI PCR fragment encoding the entire deduced open reading frame using the following PCR primers: forward primer 5′-AGCGCGGCCGCATGGCCACCGTGGTGAGGATCCCA-3′ (SEQ ID NO:44), AND reverse primer 5′-AGCGCGGCCGCTTATTCAGGTTTTCGACATGTAATGATG-3′ (SEQ ID NO:45).
• PCR amplification was achieved using Pfu polymerase, and DNA of EST sah1c.pk004.g2 was used as the template. The product of this PCR reaction was purified by agarose gel electrophoresis and subcloned into pCR-Script-AMP (Stratagene) as described in the manufacturer's protocol. The amplified open-reading frame of the soybean gamma-tocopherol methyltransferase gene was then released as a NotI fragment and cloned into the corresponding site of soybean expression vector pKS67 to generate plasmid pSC1 (SEQ ID NO:50). The plasmid pKS67 was prepared by replacing in pRB20 (described in U.S. Pat. No. 5,846,784, incorporated herein by reference) the 800bp Nos 3′ fragment, with the 285bp Nos 3′ fragment containing the polyadenylation signal sequence and described in Depicker et al. (1982)J. Mol. Appl. Genet. 1:561-573. Ligation products were transformed intoE. coliand recombinant clones were selected using hygromycin B selection.
• Restriction digestion of plasmid DNA was used to identify cultures harboring plasmid DNA in which the start codon of the soybean gamma-tocopherol methyltransferase cDNA was in close proximity to the transcription start site of the soybean β-conglycinin promoter. In this plasmid construct, henceforth referred to as SC1, the soybean gamma-tocopherol methyltransferase cDNA is under the control of a 617 bp fragment of the soybean β-conglycinin promoter. The polyadenylation signal for the HGGT transcript is derived from the terminator of the phaseolin gene. Plasmid SC1 (SEQ ID NO:50) contains hygromycin B phosphotransferase gene under control of the cauliflower mosaic 35S promoter, which allows for selection of transformed plant cells by resistance to the antibiotic hygromycin B. Plasmid DNA of SC1 was used to generate transgenic somatic embryos of soybean as described below.
• Transformation of Soybean Somatic Embryo Cultures:
• The following stock solutions and media were used for transformation and propagation of soybean somatic embryos:

  Stock Solutions

  		(g/L)
  	MS Sulfate 100x
  	stock
  	MgSO4•7H2O	37.0
  	MnSO4•H2O	1.69
  	ZnSO4•7H2O	0.86
  	CuSO4•5H2O	0.0025
  	MS Halides 100x
  	stock
  	CaCl2•2H2O	44.0
  	KI	0.083
  	CoCl2•6H2O	0.00125
  	KH2PO4	17.0
  	H3BO3	0.62
  	Na2MoO4•2H2O	0.025
  	Na2EDTA	3.724
  	FeSO4•7H2O	2.784
  	B5 Vitamin stock
  	myo-inositol	100.0
  	nicotinic acid	1.0
  	pyridoxine HCl	1.0
  	thiamine	10.0

  Media

  	SB55 (per Liter)
  	10 mL of each MS stock
  	1 mL of B5 Vitamin stock
  	0.8 g NH4NO3
  	3.033 g KNO3
  	1mL 2,4-D (10 mg/mL stock)
  	0.667 g asparagine
  	pH 5.7
  	SB103 (per Liter)
  	1 pk. Murashige & Skoog salt
  	mixture*
  	60 g maltose
  	2 g gelrite
  	pH 5.7
  	SB148 (per Liter)
  	1 pk. Murashige & Skoog salt
  	mixture*
  	60 g maltose
  	1 mL B5 vitamin stock
  	7 g agarose
  	pH 5.7
  	*(Gibco BRL)

• Soybean embryonic suspension cultures were maintained in 35 mL liquid media (SB55) on a rotary shaker (150 rpm) at 28° C. with a mix of fluorescent and incandescent lights providing a 16 hour day/8 hour night cycle. Cultures were subcultured every 2 to 3 weeks by inoculating approximately 35 mg of tissue into 35 mL of fresh liquid media.
• Soybean embryonic suspension cultures were transformed with the plasmid containing the gamma-tocopherol methyltransferase sequence by the method of particle gun bombardment (see Klein et al. (1987)Nature327:70-73) using a DuPont Biolistic PDS1000/He instrument. Five μL of pKS93s plastid DNA (1 mg/L), 50 μL Cal₂(2.5 M), and 20 μL spermdine (0.1 M) were added to 50 μL of a 60 mg/mol 1 mm gold particle suspension. The particle preparation was agitated for 3 minutes, spun on a microphage for 10 seconds and the supernatant removed. The DNA-coated particles were then washed once with 400 μL of 70% ethanol and resuspended in 40 μL of anhydrous ethanol. The DNA/particle suspension was sonicated three times for 1 second each. Five μL of the DNA-coated gold particles were then loaded on each macro carrier disk.
• Approximately 300 to 400 mg of two-week-old suspension culture was placed in an empty 60 mm×15 mm petri dish and the residual liquid removed from the tissue using a pipette. The tissue was placed about 3.5 inches away from the retaining screen and bombarded twice. Membrane rupture pressure was set at 1100 psi and the chamber was evacuated to −28 inches of Hg. Two plates were bombarded, and following bombardment, the tissue was divided in half, placed back into liquid media, and cultured as described above.
• Fifteen days after bombardment, the liquid media was exchanged with fresh SB55 containing 50 mg/mL hygromycin. The selective media was refreshed weekly. Six weeks after bombardment, green, transformed tissue was isolated and inoculated into flasks to generate new transformed embryonic suspension cultures.
• Transformed embryonic clusters were removed from liquid culture media and placed on a solid agar media, SB103, containing 0.5% charcoal to begin maturation. After one week, embryos were transferred to SB103 media minus charcoal. After five weeks on SB103 media, maturing embryos were separated and placed onto SB148 media. During maturation embryos were kept at 26° C. with a mix of fluorescent and incandescent lights providing a 16 hour day/8 hour night cycle. After three weeks on SB148 media, embryos were analyzed for the expression of the tocopherols. Each embryonic cluster gave rise to 5 to 20 somatic embryos.
• Non-transformed somatic embryos were cultured by the same method as used for the transformed somatic embryos.
• Analysis of Transformed Somatic Embryos:
• At the end of the sixth week on SB148 medium, somatic embryos were harvested from 25 independently transformed lines. Somatic embryos were collected in pools of five and weighed for fresh weight. Excess embryos were stored in 96-well plates at −80° C. The pooled somatic embryos were lyophilized for 18 hours and the dry weight measured. The lyophilized somatic embryos were briefly pulverized with a hand held Potter homogeniser and then 600 μL of heptane added and the samples incubated for 24 hours in the dark at room temperature to extract oils and tocopherols. The heptane was decanted and a further 300 μL added to the samples. The extracts were combined and centrifuged (5 minutes, 12000 g). The supernatant was stored in amber hulk auto sampler vials at −20° C. prior to analysis.
• HPLC analysis of the extracts was carried out using an HP1100 system (Agilent Technologies) 25 μL of the heptane sample was applied to a Lichrosphere Si 60 column (5 micron, 4×12.5 mm). The column was eluted with heptane/isopropanol (98:2 v/v) at a flow rate of 1 mL/min. After six minutes all four tocopherol isomers were eluted, as detected by a HP1100 fluorescence detector (Excitation wavelength 295 nm, emission wavelength 330 nm). Individual tocopherol standards (Matreya) were diluted with HPLC grade heptane to levels between 1 and 200 ng/μL to construct a 6-point external standard curve. Tocopherols in each oil were quantified using a standard curve run on the same day as the samples. The sum of tocopherol peak areas of samples from a non-transformed control line were compared with those of 25 independent gamma-tocopherol methyltransferase-transformed, hygromycin resistant lines.
• Several events were identified that showed over-expression of the soybean gamma-tocopherol methyltransferase gene. In many of the lines 80% of the total tocol fraction was comprised of alpha-tocopherol in contrast to untransformed soybean embryos where gamma-tocopherol constitutes the dominant tocol molecule. Soybean plants were generated from clonal tissue derived from ten independent transgenic soybean events with high levels of alpha-tocopherol. Several plants were generated for each of the ten events. Five T1 seed from each transgenic event were subjected to HPLC analysis to determine the composition of the tocopherol fraction. Briefly, individual dry beans were homogenized using a tissue pulverizer (Genogrinder). Approximately 30 mg of tissue powder were extracted with 600 μL for 2 hours at ambient temperature. The heptane extract was cleared by brief centrifugation. Tocol composition of the heptane extracts was analyzed by HPLC as described previously. Percent alpha-tocopherol of T1 seed is summarized in Table 5.

  TABLE 5
  Percent alpha-Tocopherol of T1 Seed

  	Seed #	Seed #	Seed #	Seed #	Seed #
  Event	1	2	3	4	5

  719/1/1/A	5.8	4.9	4.2	6.9	6.7
  719/1/1/B	8.4	5.6	7.0	8.8	7.6
  719/1/1/C	6.3	2.8	2.5	4.8	5.7
  719/1/2/A	52.4	56.5	53.0	47.0	51.1
  719/1/2/B	56.7	5.0	43.9	11.4	5.4
  719/1/2/C	41.9	44.4	2.9	42.7	5.9
  719/1/3/A	18.4	14.8	22.5	6.5	16.7
  719/1/4/A	7.0	5.3	11.7	5.6	10.6
  719/1/4/B	2.5	4.9	2.0	5.3	1.0
  719/1/5/A	34.1	52.9	31.2	37.6	9.2
  719/1/5/B	7.7	10.4	61.7	60.9	57.8
  719/1/8/A	30.7	15.2	33.9	42.4	53.1
  719/1/10/A	8.2	75.0	86.0	79.4	80.5
  719/1/10/B	85.3	81.2	8.0	7.4	80.1
  719/1/10/C	80.4	79.0	80.0	83.8	86.8
  719/1/13/A	14.6	9.1	7.3	10.2	9.2
  719/1/13/B	4.5	83.0	6.0	81.3	7.2
  719/1/13/C	78.1	9.5	9.7	9.2	10.7
  719/1/13/D	12.8	11.4	11.5	7.6	10.8
  719/1/13/E	8.5	11.5	14.2	14.0	10.9
  720/4/1/A	16.4	6.1	7.1	5.1	8.9
  720/4/2/A	7.2	79.6	73.1	50.9	34.7
  720/4/2/B	58.3	54.6	52.9	51.7	62.6
  720/4/2/C	7.0	53.7	59.8	79.1	42.7
  721/7/1/A	8.4	6.6	7.2	6.4	8.7

• Event 719.1.10 was selected for advancement. The segregation of the high alpha-tocopherol trait in T1 seed indicated that this event has a single locus insertion of the over-expressed gamma-tocopherol methyltransferase gene. T1 plants were allowed to self and T2 seed selections from individual plants were subjected to HPLC analysis of individual seed. T2 seed selections were identified that no longer segregated seed with the low alpha-tocopherol content (alpha-tocopherol<10% of total tocol). Seed from these selections were planted and bulk seed that were homozygous of the transgene were harvested from these T2 plants.
• Quantitative analysis of tocopherols of T3 seed was conducted as follows. Soybeans were ground in a FOSS tecator sample mill (FOSS, USA) using a 1 mm screen. 200 mg of tissue were extracted in 5 mL of heptane for two hours; alpha-tocopherol acetate was added as internal standard at a final concentration of 38 μg mL⁻¹. 10 μL of filtered heptane extract was subjected to HPLC using a Lichrospher column (250-4 HPLC cartridge, Si60, 5 μM particle size) using heptane containing 0.75% isopropanol as mobile phase at a flow rate of 1 mL min⁻¹. External standards of all four tocopherols and tocotrienols (2.5 μg mL⁻¹) separated under identical conditions were used for tocol quantitation. Tocols were detected using a fluorescence detector using excitation and emission wavelengths of 295 nm, 330 nm, respectively. Table 6 indicates that EMSP 719.1.10 expresses high level of gamma-tocopherol methyltransferase activity indicated by the nearly quantitative conversion of gamma- and delta- to alpha- and beta-tocopherol, respectively. Applicants note that no tocotrienols could be detected.

  TABLE 6
  Tocol Composition of Homozygous T3 Seed of Event EMSP 719.1.10

  	alpha-	beta-	gamma-	delta-
  	tocopherol	tocopherol	tocopherol	tocopherol	tocopherol

  ppm	148	29	5	3	183
  %	77	15	2	1

  
  Generation of a Transgenic Soybean Line with Seed-Preferred Expression of the Barley HGGT Gene:
• A DNA fragment was generated by PCR. The new DNA fragment contains the complete open reading frame (1224 bp; SEQ ID NO:46) of the barley HGGT cDNA flanked at 5′ and 3′ position by DNA sequences recognized by the restriction enzyme NotI. Briefly, the modified HGGT cDNA was amplified from a barley developing seed cDNA library (see PCT Publication No. WO 03/082899) using oligonucleotide primers that include NotI sites that start four nucleotides upstream of the start codon and two nucleotides downstream of the stop codon of the HGGT cDNA sequence, respectively. The sequences of the sense and antisense oligonucleotide primers used in this reaction were as follows:

  (SEQ ID NO:47)

  	5′-ttgcggccgcAGGATGCAAGCCGTCACGGCGGCAGCCG-3′
  	and

  (SEQ ID NO:48)

  5′-ttgcggccgcTTCACATCTGCTGGCCCTTGTAC-3′.

  
  (Note: The lower case, underlined nucleotide sequences correspond to added NotI restriction sites.) PCR amplification was achieved using Pfu polymerase, and an aliquot of the barley developing seed cDNA library described in PCT Publication No. WO 03/082899 was used as the template. The product of this PCR reaction was purified by agarose gel electrophoresis and subcloned into pCR-Script-AMP (Stratagene) as described in the manufacturer's protocol.
• The amplified open-reading frame of the barley HGGT was then released as a NotI fragment and cloned into the corresponding site of soybean expression vector pKS123 (construction described below) to generate plasmid pSC38 (SEQ ID NO:49).
• The construction of vector pKS123 was previously described in PCT Publication No. WO 02/008269 (the contents of which are hereby incorporated by reference). Briefly, plasmid pKS123 contains the hygromycin B phosphotransferase gene (HPT) (Gritz, L. and Davies, J. (1983)Gene25:179-188), flanked by the T7 promoter and transcription terminator (T7prom/hpt/T7term cassette), and a bacterial origin of replication (ori) for selection and replication in bacteria (e.g.,E. coli). In addition, pKS123 also contains the hygromycin B phosphotransferase gene, flanked by the 35S promoter (Odell et al.Nature(1985) 313:810-812) andNOS 3′ transcription terminator (Depicker et al.J. Mol. Appl. Genet. (1982) 1:561:570) (35S/hpt/NOS3′ cassette) for selection in plants such as soybean. pKS123 also contains a NotI restriction site, flanked by the promoter for the α′ subunit of β-conglycinin (Beachy et al.EMBO J. (1985) 4:3047-3053) and the 3′ transcription termination region of the phaseolin gene (Doyle, J. J. et al.J. Biol. Chem. (1986) 261:9228-9238) thus allowing for strong tissue-preferred expression in the seeds of soybean of genes cloned into the NotI site.
• Ligation products were transformed intoE. coliand recombinant clones were selected using hygromycin B selection. Restriction digestion of plasmid DNA was used to identify cultures harboring plasmid DNA in which the start codon of the HGGT cDNA was in close proximity to the transcription start site of the soybean β-conglycinin promoter. In this plasmid construct henceforth referred to as SC38, the barley HGGT cDNA is under the control of a 617 bp fragment of the β-conglycinin promoter. The polyadenylation signal for the HGGT transcript is derived from the terminator of the phaseolin gene. Plasmid SC38 contains hygromycin B phosphotransferase gene under control of the cauliflower mosaic 35S promoter, which allows for selection of transformed plant cells by resistance to the antibiotic hygromycin B. Plasmid DNA of SC38 was used to generate transgenic somatic embryos of soybean as described above.
• A total of 31 independent events were created. Analysis of tocopherols and tocotrienols was performed by HPLC analysis as described above. Eight events could be identified that contained detectable levels of tocotrienols indicating that in these transgenic events the barley HGGT enzyme was expressed. Tocotrienol levels are below detection limits of fluorescence detection in unmodified leaf and seed tissue of soybean. Transgenic soybeans plants were generated from somatic embryo tissue of one event (1052.5.2). A total of eight T1 seed were subjected analysis of tocopherols and tocotrienols by HPLC of these six seed contained detectable levels of tocotrienols. The segregation of the tocotrienol trait in T1 seed indicated that this event contains a single locus insertion of the β-conglycinin::HGGT expression cassette.
• Nineteen randomly selected T1 seed were grown and T2 seed were selected from individual plants. Initially, eight seed from each T2 progeny were subjected to HPLC analysis. This analysis allowed Applicants to identify five T2 progeny that did not produce seed lacking tocotrienols. The non-segregating nature of these progeny was further confirmed through analysis of another eight seed by HPLC. One of the homozygous T2 seed selections was used to produce bulked T3 seed. This seed material was used for quantitative tocol analysis and these results are found in Table 7. Table 7 shows that soybeans over-expressing the HGGT gene from barley accumulate only gamma- and delta-tocotrienol. No alpha- or beta-tocotrienol could be detected in these transgenic lines.

  TABLE 7
  Tocol Composition of Homozygous T3 Seed of Event EMSP 1052.5.2

  	alpha-	beta-	gamma-	delta-
  	tocopherol	tocopherol	tocopherol	tocopherol	tocopherol
  ppm	12	7	94	82	196
  %	0	0	3	3
  	alpha-	beta-	gamma-	delta-
  	tocotrienol	tocotrienol	tocotrienol	tocotrienol	tocotrienol
  ppm	0	0	1329	1212	2540
  %	0	0	49	44

• The tocotrienol profile of soybeans expressing the HGGT protein from barley indicate that there is no detectable activity converting gamma- and delta-tocotrienols to alpha- and beta-tocotrienols, respectively. Although not to be limited by theory, two possible scenarios could explain the lack of conversion of gamma- and delta-tocotrienol to alpha- and beta-tocotrienols in HGGT-expressing seed of dicotyledoneous plants such as soybean. First, gamma-tocopherol methyltransferase enzymes from plants that do not synthesize tocotrienols may not accept tocotrienol substrates. According to this scenario, gamma-tocopherol methyltransferase enzymes from monocotyledoneous plants have evolved into catalysts for tocotrienol methylation and their co-expression with HGGT would be required for biosynthesis of high levels of alpha- and beta-tocotrienols in dicots. Second, gamma-tocopherol methyltransferase enzymes from dicots may be effective enzymes for synthesis of alpha- and beta-tocotrienols, but their endogenous expression level is too low to achieve conversion of tocotrienol substrates (i.e., the gamma-tocopherol methyltransferase enzymes may be saturated with tocopherol substrates from the over-expression of HGGT).
• Combination of Traits for Over-Expression of HGGT and Gamma-Tocopherol Methyltransferase by Genetic Crossing:
• EMSP 719.1.10 was crossed to EMSP 1052.5.2 to test the feasability of the soybean gamma-tocopherol methyltransferase enzyme for biosynthesis of alpha -and beta-tocotrienol. A total of 20 F1 seed was generated. Quantitative analysis of tocol composition of F1 seed was conducted on a total of four F1 seed and the results are found in Table 8.

  TABLE 8
  Tocol Composition of F1 Seed Containing Transgenes for Seed-preferred
  Over-expression of the HGGT Gene from Barley and
  the gamma-Tocopherol Methyltransferase Gene from Soybean

  		alpha-	beta-	gamma-	delta-
  		tocopherol	tocopherol	tocopherol	tocopherol	tocopherol
  EMSP 1052.5.2	ppm %	11	5	93	74	184
  		0.8	0.4	6	5
  EMSP 1052.5.2;	ppm %	143	81	0	2	226
  EMSP 719.1.10		14	8	0	0
  		alpha-	beta-	gamma-	delta-
  		tocotrienol	tocotrienol	tocotrienol	tocotrienol	tocotrienol
  EMSP 1052.5.2	ppm %	0	0	581	681	1261
  		0	0	40	47
  EMSP 1052.5.2;	ppm %	274	289	54	146	763
  EMSP 719.1.10		28	29	5	15

• Comparison of the tocol profile of EMSP 1052.5.2 to that of F1 beans of a cross of EMSP 1052.5.2 to EMSP 719.1.10 reveals dramatic differences. Whereas alpha-tocotrienol is not detectable in the 1052.5.2 parent, it constitutes the second most abundant tocotrienol species in the crossed material. Applicants note that gamma-tocotrienol is almost completely converted to alpha-tocotrienol. The soybean gamma-tocopherol methyltransferase enzyme evidently also converts delta- to beta- tocotrienol. The lower total tocotrienol concentration of the F1 beans (763 ppm compared to 1,261 ppm in the 1052.5.2 parent) may be attributed to the heterozygous state of the HGGT transgene in the F1 seed or could indicate that the two β-conglycinin promoter-driven transcripts are subject to transcriptional or post-transcriptional gene silencing due to identical promoter and/or 5′UTR sequences. F1 seed were germinated in soil and allow to self. A total of forty-eight F2 seed was analyzed by HPLC and the results are found in Table 9.

  TABLE 9
  Tocol Composition (percent of total tocopherols (tocph.) and tocotrienols (toct.))
  for F2 Progeny of a Cross of EMSP 1052.5.2 to EMSP 719.1.10

  	alpha-	beta-	gamma-	delta-	alpha-	beta-	gamma-	delta-	tocph.	toct.
  No.	tocph.	tocph.	tocph.	tocph.	toct.	toct.	toct	toct.	(ppm)	(ppm)

  1	10	7	0	0	31	37	5	10	217	1128
  2	10	7	0	0	31	38	5	9	248	1220
  3	10	6	0	0	30	36	9	10	196	1067
  4	13	7	0	0	30	37	5	8	279	1124
  5	9	6	0	0	30	33	9	13	239	1366
  6	8	6	0	0	30	39	6	11	229	1408
  7	12	7	0	0	30	33	8	10	271	1098
  8	11	7	0	0	30	34	9	9	258	1158
  9	10	6	0	0	29	34	7	13	227	1177
  10	15	7	0	0	29	31	8	9	265	903
  11	10	7	0	0	28	29	12	14	199	1005
  12	8	6	0	0	28	36	8	14	227	1449
  13	12	6	0	0	28	32	12	10	255	1144
  14	9	7	0	0	28	35	8	13	227	1190
  15	10	7	0	0	27	37	7	12	240	1196
  16	13	8	0	0	27	31	7	14	263	996
  17	11	7	0	0	27	34	8	13	228	1017
  18	11	8	0	0	27	33	7	14	261	1095
  19	10	7	0	0	27	36	7	12	256	1207
  20	13	7	0	0	27	31	10	12	210	822
  21	11	7	0	0	26	39	6	10	250	1108
  22	8	7	0	0	26	40	7	12	228	1260
  23	8	6	0	0	26	35	8	17	230	1409
  24	12	7	0	0	26	28	14	14	193	818
  25	10	8	0	0	26	37	6	13	265	1155
  26	7	7	0	0	25	41	7	13	237	1472
  27	8	7	0	0	24	38	7	15	224	1262
  28	10	7	0	0	24	32	9	17	282	1385
  29	7	6	0	0	24	37	8	18	176	1171
  30	9	7	0	0	21	29	13	21	219	1111
  31	2	1	7	4	1	0	46	40	238	1554
  32	1	0	4	3	0	0	45	45	232	2284
  33	1	1	5	3	0	0	47	43	190	1740
  34	1	1	6	4	0	0	44	44	231	1784
  35	2	0	6	3	0	0	51	37	225	1788
  36	2	1	5	4	0	0	41	46	204	1499
  37	86	14	0	0	0	0	0	0	244	0
  38	84	16	0	0	0	0	0	0	253	0
  39	83	17	0	0	0	0	0	0	183	0
  40	82	18	0	0	0	0	0	0	216	0
  41	81	17	1	1	0	0	0	0	317	0
  42	80	19	1	0	0	0	0	0	221	0
  43	78	19	2	1	0	0	0	0	226	0
  44	34	3	56	7	0	0	0	0	225	0
  45	26	3	59	11	0	0	0	0	337	0
  46	23	2	64	10	0	0	0	0	213	0
  47	13	2	69	17	0	0	0	0	261	0
  48	12	2	70	16	0	0	0	0	216	0

• Tocol analysis of forty-eight F2 seed revealed 30 F2 seed that expressed both transgene-related traits (see numbers 1-30), six and seven seed with only HGGT or gamma-tocopherol methyltransferase traits, (see numbers 31-36 and 37-43, respectively), and five wild-type seed (see numbers 44-48). These findings are very close to the expected segregation of two unlinked, dominant traits in the F2 generation of a cross of two parents that were homozygous for one of each of the dominant traits. The expected frequency of F2s with both transgenic traits is 62.5% (30/48). The expected frequency of F2s with a single transgenic trait or no transgenic trait is 12.5% (6/48).
• F2 progeny with both transgene-related traits were found to contain at least 258 ppm and as much as 487 ppm alpha-tocotrienol and at least 278 ppm and as much as 701 ppm beta-tocotrienol. The oil content of the heptane extracts was determined by derivatization with sodium methoxide followed by GC analysis. Oil was calculated from the tocotrienol concentrations expressed as ppm. F2 progeny with both transgene-related traits contained an oil with at least 1,670 ppm and as much as 2,940 alpha-tocotrienol and at least 1,800 ppm and as much as 4,080 ppm beta-tocotrienol. Applicants also tested for a possible negative effect of the high alpha- and beta-tocotrienol content on seed weight. To this end, seed weight of the forty-eight F2 seed was plotted against alpha-tocotrienol content. No correlation between seed weight and alpha-tocotrienol content could be detected.
• In summary, gamma-tocopherol methyltransferase enzyme from soybean can efficiently use tocotrienol substrates, and the foregoing is a method to generate a seed or an extracted oil with high levels of alpha- and beta-tocotrienol. The alpha-tocotrienol content of soybeans over-expressing barley HGGT and the soybean gamma-tocopherol methyltransferase gene exceeds that of any non-transgenic seed or oil described previously by at least one order of magnitude (Packer et al. (2001)J. Nutr.131:369S-373S; Bertoli et al. (1998)JAOCS75:1037-1040; PCT Publication No. WO 00/072862). These results further demonstrate the ability to produce alpha- and beta-tocotrienols in a crop plant that does not normally accumulate these antioxidant molecules through the transgenic expression of nucleic acid fragments encoding HGGT and gamma-tocopherol methyltransferase polypeptides.
EXAMPLE 4Production of Alpha- and Beta-Tocotrienols in Maize (Zea mays) Seed
• Maize oil, which is derived primarily from the embryo of maize seeds, is typically enriched in tocopherols but contains little or no tocotrienols (The Lipid Handbook, 2nd Edition, Gunstone, F. D., et al., Eds., Chapman and Hall, London, 1994, pp. 129-131). Embryo-preferred expression of the barley HGGT gene in maize leads to accumulation of high levels of tococtrienols. 70-80% of the tocotrienols accumulate in the form of gamma-tocotrienol and only 5-10% of the total tocotrienol fraction is represented by alpha-tocotrienol (see PCT Publication No. WO 03/082899; U.S. Application No. 2004/0034886, Cahoon et al. (2003)Nat. Biotechnol.21:1082-1087.
• Based on results disclosed in Examples 1, 2 and 3 of the instant application, the barley HGGT cDNA (bdl2c.pk006.o2; SEQ ID NO:2) and soybean gamma-tocopherol methyltransferase (sah1c.pk004.g2; SEQ ID NO:12) can be expressed in seed embryo of maize to increase the tocol antioxidant content of this tissue and the extracted oil to produce a novel tocol composition that is dominated by alpha- and beta-tocotrienols. As described below, this result can be achieved by transforming maize with an expression cassette comprising the soybean gamma-tocopherol methyltransferase open reading frame operably linked on its 5′ end to an embryo preferred promoter, such as the promoter for the maize 16 kDa oleosin gene (Lee, K. and Huang, A. H. (1994)Plant Mol. Biol.26:1981-1987) and the barley HGGT open reading frame operably linked to the maize embryo abundant (EAP1) promoter and terminator.
• An expression cassette comprising the promoter from the maize 16 kDa oleosin gene (OLE PRO), the coding sequence of soybean gamma-tocopherol methyltransferase (SEQ ID NO:14) derived from cDNA clone sah1c.pk001.k8:fis (SEQ ID NO:13) (PCT Publication No. WO 00/032757) and the polyadenylation signal sequence/terminator from the nopaline synthase (NOS) gene ofAgrobacterium tumefaciensis constructed using methods and technologies known in the art. A second expression cassette comprises the barley HGGT coding sequence (PCT Publication No. WO 03/082899; U.S. Application No. 2004/0034886) under the transcriptional control of the maize embryo abundant protein (EAP1) promoter and terminator, with the maize ADH1 INTRON1 inserted between the promoter and coding sequence for enhanced expression. The two expression cassettes are linked, together with a gene encoding a selectable marker, in a binary vector suitable forAgrobacterium-mediated transformation of maize.
• Similarly, a vector may be created as described above, with the maize gamma-tocopherol methyltransferase (SEQ ID NO:16) derived from cDNA clone p0060.coran49r:fis (SEQ ID NO:15) (PCT Publication No. WO 00/032757) used in place of the soybean gamma-tocopherol methyltransferase, using the same promoter/terminator elements and HGGT expression cassette already described. Furthermore, one skilled in the art understands that the homogentisate geranylgeranyl transferases (HGGT) and gamma-tocopherol methyltransferases found in Table 1 and Table 2, respectively, may also be expressed in maize to demonstrate the feasability of these cDNA for alpha and beta-tocotrienol production in transgenic plants.
• AnAgrobacterium-based protocol can be used for the transformation of maize (see below). The resulting binary vector is introduced intoAgrobacteriumLBA4404 (PHP10523) cells, preferably by electroporation. An in vivo recombination generates a cointegrate plasmid between the introduced binary vector and the vir plasmid (PHP10523) resident in theAgrobacteriumcells. The resultingAgrobacteriumcells are used to transform maize.
• Transformation of Maize Mediated byAgrobacterium:
• Freshly isolated immature embryos of maize, about ten days after pollination (DAP), can be incubated with theAgrobacterium. The preferred genotype for transformation is the highly transformable genotype Hi-II (Armstrong (1991) Maize Gen. Coop. Newsletter 65:92-93). An F1 hybrid created by crossing a Hi-II with an elite inbred may also be used. AfterAgrobacteriumtreatment of immature embryos, the embryos can be cultured on medium containing toxic levels of herbicide. Only those cells that receive the herbicide resistance gene, and the linked gene(s), grow on selective medium. Transgenic events so selected can be propagated and regenerated to whole plants, produce seed, and transmit transgenes to progeny.
• Preparation ofAgrobacterium:
• The engineeredAgrobacterium tumefaciensLBA4404 can be constructed to contain plasmids for seed-preferred expression of HGGT and gamma-tocopherol methyltransferase genes, as disclosed in U.S. Pat. No. 5,591,616 (the contents of which are hereby incorporated by reference). To use the engineered construct in plant transformation, a master plate of a single bacterial colony transformed with plasmids for seed-preferred expression of HGGT and gamma-tocopherol methyltransferase genes can be prepared by inoculating the bacteria on minimal AB medium and allowing incubation at 28° C. for approximately three days. (The composition and preparation of minimal AB medium has been previously described in PCT Publication No. WO 02/009040 (the contents of which are hereby incorporated by reference). A working plate can then be prepared by streaking the transformedAgrobacteriumon YP medium (0.5% (w/v) yeast extract, 1% (w/v) peptone, 0.5% (w/v) sodium chloride, 1.5% (w/v) agar) that contains 50 μg/mL of spectinomycin.
• The transformedAgrobacteriumfor plant transfection and co-cultivation can then be prepared one day prior to maize transformation. Into 30 mL of minimal A medium (prepared as described in PCT Publication No. WO 02/009040) in a flask was placed 50 μg/mL spectinomycin, 100 μM acetosyringone, and about a ⅛ loopful ofAgrobacteriumfrom a one to two-day-old working plate. TheAgrobacteriumcan then be grown at 28° C. with shaking at 200 rpm for approximately fourteen hours. At mid-log phase, theAgrobacteriumcan be harvested and resuspended at a density of 3 to 5×108 CFU/mL in 561Q medium that contains 100 μM acetosyringone using standard microbial techniques. The composition and preparation of 561Q medium was described in PCT Publication No. WO 02/009040.
• Immature Embryo Preparation:
• Nine to ten days after controlled pollination of a maize plant, developing immature embryos are opaque and 1-1.5 mm long. This length is the optimal size for infection with the PHP18749-transformedAgrobacterium. The husked ears can be sterilized in 50% commercial bleach and one drop Tween-20 for thirty minutes, and then rinsed twice with sterile water. The immature embryos can then be aseptically removed from the caryopsis and placed into 2 mL of sterile holding solution consisting of medium 561Q that contains 100 μM of acetosyringone.
• AgrobacteriumInfection and Co-Cultivation of Embryos:
• The holding solution can be decanted from the excised immature embryos and replaced with transformedAgrobacterium. Following gentle mixing and incubation for about five minutes, theAgrobacteriumcan be decanted from the immature embryos. Immature embryos were then moved to a plate of 562P medium, the composition of which has been previously described in PCT Publication No. WO 02/009040. The immature embryos can be placed on this media scutellum surface pointed upwards and then incubated at 20° C. for three days in darkness. This can be followed by incubation at 28° C. for three days in darkness on medium 562P that contains 100 μg/mL carbenecillin as described in U.S. Pat. No. 5,981,840.
• Selection of Transgenic Events:
• Following incubation, the immature embryos can be transferred to 5630 medium, which can be prepared as described in PCT Publication No. WO 02/009040. This medium contains Bialaphos for selection of transgenic plant cells as conferred by the BAR gene that is linked to barley HGGT expression cassette. At ten to fourteen-day intervals, embryos were transferred to 5630 medium. Actively growing putative transgenic embryogenic tissue can be after six to eight weeks of incubation on the 5630 medium.
• Regeneration of T₀Plants:
• Transgenic embryogenic tissue is transferred to 288W medium and incubated at 28° C. in darkness until somatic embryos matured, or about ten to eighteen days. Individual matured somatic embryos with well-defined scutellum and coleoptile are transferred to 272 embryo germination medium and incubated at 28° C. in the light. After shoots and roots emerge, individual plants are potted in soil and hardened-off using typical horticultural methods.
• 288W medium contains the following ingredients: 950 mL of deionized water; 4.3 g of MS Salts (Gibco); 0.1 g of myo-inositol; 5 mL of MS Vitamins Stock Solution (Gibco); 1 mL of zeatin (5 mg/mL solution); 60 g sucrose; 8 g of agar (Sigma A-7049, Purified), 2 mL of indole acetic acid (0.5 mg/mL solution*); 1 mL of 0.1 mM ABA*; 3 mL of Bialaphos (1 mg/mL solution*); and 2 mL of carbenicillin (50 mg/mL solution). The pH of this solution is adjusted to pH 5.6. The solution is autoclaved and ingredients marked with an asterisk (*) are added after the media has cooled to 60° C.
• Medium 272 contains the following ingredients: 950 mL of deionized water; 4.3 g of MS salts (Gibco); 0.1 g of myo-inositol; 5 mL of MS vitamins stock solution (Gibco); 40 g of Sucrose; and 1.5 g of Gelrite. This solution is adjusted to pH 5.6 and then autoclaved.
EXAMPLE 5Expression of Chimeric Genes in Microbial Cells
• The cDNAs encoding the instant HGGT and gamma-tocopherol methyltransferase polypeptides can be used to produce alpha- and beta-tocotrienols in microbes such as algal and cyanobacterial cells that contain an operable tocopherol biosynthetic pathway. Expression of cDNAs encoding the instant HGGT polypeptides in these cells are expected to result in the condensation of geranylgeranyl pyrophosphate and homogentisate. The product of the HGGT reaction 2-methyl-6-geranylgeranylbenzoquinol can then be converted to alpha- and beta-tocotrienols by tocopherol biosynthetic enzymes native to the host microbial cell and the instant gamma-tocopherol methyltransferase polypeptides. Tocotrienols can be produced in microbes by linking the cDNAs encoding the instant HGGT and gamma-tocopherol methyltransferase polypeptides with promoter elements that are suitable to direct gene expression in the selected host cell. The resulting chimeric genes can be introduced into the host microbial cell using techniques such as homologous recombination (Williams, J. G. K. (1988)Methods Enzymol.167:766-778; Legarde, D. et al. (2000)App. Environ. Microbiol.66:64-72). Host cells transformed with cDNAs for the instant HGGT and gamma-tocopherol methyltransferase polypeptides operably linked to functional promoters can then be analyzed for tocotrienol production using techniques described in Example 1.
EXAMPLE 6Production of Alpha- and Beta-Tocotrienol in Plant Cells
• The cDNAs encoding the instant HGGT and gamma-tocopherol methyltransferase polypeptides can be used to produce alpha- and beta-tocotrienols in plant cells. Even higher levels of alpha- and beta-tocotrienol production may be achieved when genes encoding the instant HGGT and gamma-tocopherol methyltransferase polypeptides are co-expressed with genes that encode enzymes that participate either in the conversion of plastidic chorismate pools to homogentisate or in the conversion of 2-methyl-6-prenylbenzoquinol to 2,3-methyl-6-prenylbenzoquinol. To this end, transgenic plants are generated with DNA constructs that provide constitutive- or seed-specific expression of bifunctional chorismate mutase-prephenate dehydratase genes (TYRA) of bacterial or fungal origin and p-hydroxyphenylpyruvate dioxygenase genes (HPPD) and 2-methyl-6-prenylbenzoquinol methyltransferase genes (VTE3) from plants or photosynthetic bacteria. The TRYA gene products are targeted to the chloroplast by way of being fused to suitable chloroplast target peptides.
• Plant transformations are performed as described above in Examples 1-3. Transgenic lines expressing high levels TYRA, HPPD and VTE3 are identified by measuring tocochromanol content as described above in Examples 1-3. The events with high levels of tocochromanols are crossed to events generated with constructs expressing the instant HGGT and gamma-tocopherol methyltransferase polypeptides. Suitable constructs to generate the latter events are KS319 (Example 1), SC1 and SC38 (Example 2), KS270 and KS308 (Example 3). Alternatively, new DNA constructs are generated using standard methods of molecular biology that provide seed-specific or constitutive expression of five genes comprised of TYRA, HPPD, VTE3 and HGGT and gamma-tocopherol methyltransferase genes of instant invention. Plant transformations are performed as described in Examples 1-3. Transgenic lines expressing high levels of all five gene products are identified by measuring tocochromanol content of plant tissue as described in Examples 1-3.
EXAMPLE 7Production of Tocotrienols in Transgenic Soybean Lines: Molecular Stack of Barley HGGT and Maize Gamma-Tocopherol Methyltransferase
• To demonstrate the ability to produce increased levels of alpha- and beta-tocotrienols in transgenic soybean lines, the barley HGGT cDNA (bdl2c.pk006.o2; SEQ ID NO:2) and maize gamma-tocopherol methyltransferase (p0060.coran49r:fis; SEQ ID NO:15) (PCT Publication No. WO 00/032757) were used in a molecular stack (progeny with both transgene-related traits).
• A construct for seed specific expression of maize gamma-tocopherol methyltransferase in soybean was generated as follows. DNA of KS126 (see Example 1) was linearized with NotI. 5′ overhangs were completely filled in with T4 polynucleotid kinase and dephosphorylated using calf intestinal phosphatase. A restriction fragment containing the complete ORF of the maize GTMT cDNA was excised from the EST clone using restriction enzymes DraI and SnaBI and ligated to the KS126 vector. Ligation products were introduced intoE coli. Plasmid DNA was isolated form recombinant clones and subjected to restriction digests with BamHI. Plasmid clones which produced a DNA fragment of 2.8 kb when digested with BamHI contain the maize GTMT gene in an orientation in which the 5′ end of the transcript is in proximity to the 3′ end of the KTI promoter (sense orientation). This plasmid was named KS325. Its sequence is set forth as SEQ ID NO:51.
• Transgenic soybean lines were generated with plasmid DNA of KS270 (see Example 1) and KS325 using particle bombardment of embryogenic callus.
• KS270 provides the barley HGGT gene under control of 617 bp of the soybean β-conglycinin promoter. The polyadenylation signal for the HGGT transcript is derived from the terminator of the phaseolin gene (from the beanPhaseolus vulgaris; Doyle et al. (1986)J. Biol. Chem.261:9228-9238). The plasmid also contains the cDNA of a sulfonylurea-resistant variant of the soybean ALS gene that is under control of 1217 bp of the SAMS promoter. The polyadenylation signal for the HGGT transcript is derived from the terminator of the soybean ALS gene.
• KS325 provides the gamma-tocopherol methyltransferase gene from maize under the control of 2090 bp of the soybean Kti promoter. The polyadeylation signal for the gamma-tocopherol methyltransferase transcript is derived from the terminator of the Kti gene. KS325 also provides a hygromycin B phosphotransferase (HPT) resistance gene (Gritz et al. (1983)Gene25:179-188) that is under control of 1408 bp of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985)Nature313:810-812). The polyadenylation signal for the hygromycin resistance gene is derived from the terminator of nopaline synthase gene from the T-DNA of the Ti plasmid ofAgrobacterium tumefaciens.
• Soybean embryogenic suspension cultures were transformed with DNA plasmids KS270 in conjunction with KS325 by the method of particle gun bombardment (Klein et al. (1987)Nature(London) 327:70-73; U.S. Pat. No. 4,945,050) using a BIORAD Biolistic PDS1000/He instrument. The following stock solutions and media were used for transformation and regeneration of soybean plants:
• Stock solutions:
• Sulfate 100×Stock: 37.0 g MgSO₄.7H₂O, 1.69 g MnSO₄.H₂O, 0.86 g ZnSO₄.7H₂O, 0.0025 g CuSO₄.5H₂O
• Halides 100×Stock: 30.0 g CaCl₂.2H₂O, 0.083 g KI, 0.0025 g CoCl₂.6H₂O
• P, B, Mo 100×Stock: 18.5 g KH₂PO₄, 0.62 g H₃BO₃, 0.025 g Na₂MoO₄.2H₂O
• Fe EDTA 100×Stock: 3.724 g Na₂EDTA, 2.784 g FeSO₄.7H₂O
• 2,4-D Stock: 10 mg/mL
• Vitamin B5 1000×Stock: 10.0 g myo-inositol, 0.10 g nicotinic acid, 0.10 g pyridoxine HCl, 1 g thiamine.
• Media (per Liter):
• SB196: 10 mL of each of the above stock solutions, 1 mL B5 Vitamin stock, 0.463 g (NH₄)₂SO₄, 2.83 g KNO₃, 1mL 2,4-D stock, 1 g asparagine, 10 g Sucrose, pH 5.7
• SB103: 1 pk. Murashige & Skoog salts mixture, 1 mL B5 Vitamin stock, 750 mg MgCl₂hexahydrate, 60 g maltose, 2 g gelrite, pH 5.7.
• SB166: SB103 supplemented with 5 g per liter activated charcoal.
• SB71-4: Gamborg's B5 salts, 1 mL B5 vitamin stock, 30 g sucrose, 5 g TC agar, pH 5.7.
• To prepare tissue for transformation, soybean embryogenic suspension cultures were maintained in 35 mL liquid medium (SB196) on a rotary shaker (150 rpm) at 28° C. with fluorescent lights providing a 16 hour day/8 hour night cycle. Cultures were subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of fresh liquid media.
• In particle gun bombardment procedures it is possible to use purified 1) entire plasmid DNA; or 2) DNA fragments containing only the recombinant DNA expression cassette(s) of interest. For every seventeen bombardment transformations, 85 μL of suspension is prepared containing 1 to 90 picograms (pg) of plasmid DNA per base pair of each DNA plasmid. Both recombinant DNA plasmids were co-precipitated onto gold particles as follows. The DNAs in suspension were added to 50 μL of a 20-60 mg/mL 0.6 μm gold particle suspension and then combined with 50 μL CaCl₂(2.5 M) and 20 μL spermidine (0.1 M). The mixture was vortexed for 5 seconds, spun in a microfuge for 5 seconds, and the supernatant removed. The DNA-coated particles were then washed once with 150 μL of 100% ethanol, vortexed and spun in a microfuge again, then resuspended in 85 μL of anhydrous ethanol. Five μL of the DNA-coated gold particles were then loaded on each macrocarrier disk.
• Approximately 150 to 250 mg of two-week-old suspension culture was placed in an empty 60 mm×15 mm petri plate and the residual liquid removed from the tissue using a pipette. The tissue was placed about 3.5 inches away from the retaining screen and each plate of tissue was bombarded once. Membrane rupture pressure was set at 650 psi and the chamber was evacuated to −28 inches of Hg. Three plates were bombarded, and, following bombardment, the tissue from each plate was divided between two flasks, placed back into liquid media, and cultured as described above.
• Seven days after bombardment, the liquid medium was exchanged with fresh SB196 medium supplemented with 30-50 mg/L hygromycin. The selective medium was subsequently refreshed weekly or biweekly. Seven weeks post-bombardment, bright green, transformed tissue was observed growing from untransformed, chlorotic or necrotic embryogenic clusters. Isolated green tissue was removed and inoculated into individual wells in six-well culture dishes to generate new, clonally-propagated, transformed embryogenic suspension cultures. Thus, each new line was treated as independent transformation event in an individual well. These suspensions can then be maintained as suspensions of embryos clustered in an immature developmental stage through subculture or they can be regenerated into whole plants by maturation and germination of individual somatic embryos.
• After two weeks in individual cell wells, transformed embryogenic clusters were removed from liquid culture and placed on solidified medium (SB166) containing no hormones or antibiotics for one week. Embryos were cultured for at 26° C. with mixed fluorescent and incandescent lights on a 16 hour day/8 hour night schedule. After one week, the cultures were then transferred to SB103 medium and maintained in the same growth conditions for 3 additional weeks.
• Somatic embryos became suitable for germination after four weeks and were then removed from the maturation medium and dried in empty petri dishes for 1 to five days. The dried embryos were then planted in SB71-4 medium where they were allowed to germinate under the same light and temperature conditions as described above. Germinated embryos were transferred to sterile soil and grown to maturity for seed production.
• A total of eighteen events were created by co-transformation with KS270 and KS325 plasmids. Tocol composition of five T1 seed was assayed for each events as follows. A seed chip (approximately 5-15 mg of tissue) was obtained from the cotyledon tissue of the seed. The chip was extracted with 100 μL of heptane for 2 hours. Tocopherol and tocotrienol was quantitated by HPLC analysis as described in Example 3.
• A total of eighteen events were generated and analyzed (see Table 10).

  TABLE 10
  Tocol Composition (percent of total tocopherols (tocph.) and tocotrienols (toct.))
  for T1 Seed Chips of Events Generated with KS270 and KS325

  	alpha-	beta-	gamma-	delta-	alpha-	beta-	gamma-	delta-	tocph.	toct.
  Event ID	tocph.	tocph.	tocph.	tocph.	toct.	toct.	toct	toct.	(ppm)	(ppm)

  4652.1.10.1A	1	1	2	3	2	1	44	46	167	2175
  4652.1.10.1B	17	2	80	0	0	0	0	0	240	0
  4652.1.10.1C	2	1	3	0	2	1	44	47	279	4711
  4652.1.10.1D	11	1	88	0	0	0	0	0	310	0
  4652.1.10.1E	2	1	4	0	4	2	42	46	317	4070
  4652.1.11.1A	1	0	3	0	0	0	44	51	156	3463
  4652.1.11.1B	1	1	4	0	0	0	47	47	127	2133
  4652.1.11.1C	1	0	4	0	0	0	50	46	96	1900
  4652.1.11.1D	20	2	78	0	0	0	0	0	270	0
  4652.1.11.1E	1	0	5	0	0	0	53	39	201	2600
  4652.1.2.1A	1	0	3	0	1	0	42	52	101	2204
  4652.1.2.1B	1	0	3	0	1	0	46	50	149	3923
  4652.1.2.1C	11	1	88	0	0	0	0	0	192	0
  4652.1.2.1D	1	0	3	0	1	0	44	51	153	3310
  4652.1.2.1E	0	0	3	0	1	0	41	54	109	2831
  4652.1.7.1A	6	4	0	0	38	41	4	7	240	2051
  4652.1.7.1B	6	4	0	0	42	40	3	5	169	1597
  4652.1.7.1C	22	2	76	0	0	0	0	0	273	0
  4652.1.7.1D	6	5	0	0	35	45	3	6	214	1756
  4652.1.7.1E	5	5	0	0	32	52	2	5	400	3670
  4652.1.8.1A	16	2	83	0	0	0	0	0	175	0
  4652.1.8.1B	0	0	4	0	0	0	47	48	115	2429
  4652.1.8.1C	17	2	82	0	0	0	0	0	160	0
  4652.1.8.1D	1	0	4	0	0	0	45	50	114	2277
  4652.1.8.1E	1	0	4	0	0	0	51	44	100	1962
  4652.2.10.1A	0	0	4	0	0	0	42	53	124	2292
  4652.2.10.1B	0	0	4	0	0	0	47	47	147	2767
  4652.2.10.1C	1	0	5	0	0	0	48	46	223	3502
  4652.2.10.1D	9	1	90	0	0	0	0	0	254	0
  4652.2.10.1E	11	2	87	0	0	0	0	0	267	0
  4652.2.11.1A	11	1	87	0	0	0	0	0	164	0
  4652.2.11.1B	6	5	0	0	37	50	0	1	197	1604
  4652.2.11.1C	7	6	0	0	36	50	0	0	466	2950
  4652.2.11.1D	12	1	86	0	0	0	0	0	209	0
  4652.2.11.1E	6	7	0	0	32	55	0	0	440	2973
  4652.2.13.1A	10	1	88	0	0	0	0	0	243	0
  4652.2.13.1B	10	1	88	0	0	0	0	0	230	0
  4652.2.13.1C	15	2	82	0	0	0	0	0	155	0
  4652.2.13.1D	11	1	88	0	0	0	0	0	284	0
  4652.2.13.1E	11	1	88	0	0	0	0	0	229	0
  4652.2.14.1A	85	14	1	0	0	0	0	0	360	0
  4652.2.14.1B	4	4	0	0	31	43	5	12	267	2796
  4652.2.14.1C	9	6	0	0	40	44	0	1	342	1855
  4652.2.14.1D	86	13	0	0	0	0	0	0	254	1
  4652.2.14.1E	5	4	0	0	32	58	0	1	262	2495
  4652.2.6.1A	6	8	0	0	32	54	0	0	353	2192
  4652.2.6.1B	65	14	0	0	15	6	0	0	378	102
  4652.2.6.1C	8	7	0	0	33	52	0	0	488	2762
  4652.2.6.1D	6	6	0	0	33	53	0	1	399	2905
  4652.2.6.1E	63	16	0	0	15	6	0	0	358	95
  4652.2.7.1A	2	1	4	0	1	1	42	49	205	2779
  4652.2.7.1B	2	1	4	0	2	1	43	48	176	2660
  4652.2.7.1C	1	1	3	0	2	1	45	48	110	2192
  4652.2.7.1D	1	1	4	0	2	1	42	50	170	2679
  4652.2.7.1E	3	1	6	0	2	1	48	40	199	1889
  4652.2.9.1A	5	4	0	0	28	31	11	22	252	2495
  4652.2.9.1B	6	5	0	0	33	40	5	11	214	1614
  4652.2.9.1C	4	2	3	0	17	8	37	29	212	2148
  4652.2.9.1D	5	4	0	0	30	33	10	19	245	2521
  4652.2.9.1E	4	2	1	0	19	14	24	36	194	2212
  4652.3.15.1A	85	14	1	0	0	0	0	0	213	0
  4652.3.15.1B	76	23	0	0	0	0	0	0	379	0
  4652.3.15.1C	13	2	86	0	0	0	0	0	183	0
  4652.3.15.1D	77	22	0	0	0	0	0	1	167	1
  4652.3.15.1E	78	21	1	0	0	0	0	0	248	0
  4652.3.17.1A	8	7	0	0	36	47	1	1	361	2029
  4652.3.17.1B	8	5	0	0	42	44	1	1	362	2419
  4652.3.17.1C	18	10	0	0	34	37	0	1	471	1198
  4652.3.17.1D	8	6	0	0	38	45	1	1	334	1941
  4652.3.17.1E	9	7	0	0	38	45	0	1	276	1392
  4652.3.3.1A	4	4	0	0	37	41	5	9	272	2905
  4652.3.3.1B	5	4	0	0	37	45	3	6	282	2714
  4652.3.3.1C	8	6	0	0	36	48	1	2	416	2608
  4652.3.3.1D	4	4	0	0	36	53	1	2	233	2390
  4652.3.3.1E	5	5	0	0	31	43	5	12	344	3319
  4652.3.5.1A	18	2	80	0	0	0	0	0	161	0
  4652.3.5.1B	21	2	77	0	0	0	0	0	192	0
  4652.3.5.1C	4	4	0	0	22	28	13	29	203	2315
  4652.3.5.1D	18	2	80	0	0	0	0	0	191	0
  4652.3.5.1E	6	4	1	0	28	27	14	20	296	2450
  4652.3.6.1A	16	2	82	0	0	0	0	0	182	0
  4652.3.6.1B	7	5	0	0	43	43	1	1	328	2451
  4652.3.6.1C	7	5	0	0	41	44	1	1	292	2060
  4652.3.6.1D	9	6	0	0	41	42	1	1	288	1654
  4652.3.6.1E	15	2	84	0	0	0	0	0	244	0
  4652.3.8.1A	30	4	66	0	0	0	0	0	137	0
  4652.3.8.1B	24	3	73	0	0	0	0	0	180	0
  4652.3.8.1C	16	2	82	0	0	0	0	0	196	0
  4652.3.8.1D	30	3	68	0	0	0	0	0	205	0
  4652.3.8.1E	44	6	49	0	0	0	0	0	194	0

• Seed chips from fifteen events contained significant levels of tocotrienol. Ten of these also contained significant levels (>150 ppm) of alpha- and beta-tocotrienol. Alpha-tocotrienol content in seed chips reached 1300 ppm in event 4652.1.7.1 E (i.e, (400+3670)×0.32=1302). For several events greater than 40% of the total tocopherol and tocotrienol content was alpha-tocotrienol. Seed chips do not provide a comprehensive picture of the oil composition of the entire seed. Therefore, the entire T1 seed from selected events were subjected to tocol analysis as described in Example 2 (see Table 11).

  TABLE 11
  Tocol Composition (percent of total tocopherols (tocph.) and tocotrienols (toct.))
  for T1 Seed of Events Generated with KS270 and KS325

  	alpha-	beta-	gamma-	delta-	alpha-	beta-	gamma-	delta-	tocph.	toct.
  Event ID	tocph.	tocph.	tocph.	tocph.	toct.	toct.	toct	toct.	(ppm)	(ppm)

  4652.1.7.1 A	5	4	0	0	31	45	3	10	261	2355
  4652.1.7.1 B	5	4	0	0	36	44	3	8	214	2162
  4652.2.11.1 B	4	5	0	0	29	59	1	2	213	2028
  4652.2.11.1C	6	7	0	0	24	62	0	0	224	1414
  4652.2.14.1C	6	6	0	0	30	53	1	3	245	1694
  4652.2.6.1 C	7	9	0	0	25	57	0	2	320	1636
  4652.2.6.1 D	7	8	0	0	27	57	0	1	327	1986
  4652.3.17.1 B	5	6	0	0	28	54	2	6	210	1688
  4652.3.17.1 D	7	6	0	0	31	51	1	4	238	1612
  4652.3.6.1 B	5	4	0	0	36	51	1	2	227	2077
  4652.3.6.1C	6	5	0	0	35	50	1	2	238	1802

• The highest whole seed alpha-tocotrienol level (847 ppm) was reached in event 4652.1.7.1. For the six events subjected to whole seed tocol analysis at least 24% and up to 36% of the total tocopherol and tocotrienol content was derived from alpha-tocotrienol. In all six events gamma- and delta-tocotrienol levels are at very low levels compared to the best transgenic event generated in similar experiments performed with the soybean GTMT sequence (Example 2). The maize GTMT provides an excellent enzyme for methylation of gamma- and delta-tocotrienol in developing soybean seed.
EXAMPLE 8Alpha-Tocotrienol Production inArabidopsis thalianaby Transgenic Expression of Barley HGGT and Maize Gamma-Tocopherol Methyltransferase
• A construct for co-expression of barley homogentisate geranylgeranyl transferase and maize gamma-tocopherol methyltransferase inArabidopsis thalianawas generated as follows. The maize GTMT expression cassette comprised of Kti promoter GTMT gene and Kti terminator was excised from KS325 (see Example 7) as a 3.6 kb fragment by complete digestion with AscI. This DNA fragment was ligated to SC38 DNA that had previously been lineraized by partial digestion with AscI. Recombinant clones were recovered and plasmid DNA was isolated using standard techniques. This new plasmid is referred to KS325×SC38. A 6.7 kb DNA fragment containing expression cassettes for barley HGGT and maize GTMT genes was excised from this plasmid by partial digestion with SalI and ligated to pZBL120 (see Example 1) linearized with SalI to give pZBL120×KS325×SC38. The T-DNA of the plant transformation vector pZBL120×KS325×SC38 is set forth as SEQ ID NO:52. TransgenicArabidopsislines were generated using pZBL20×KS325×SC38 as described in Example 1. A total of 38 lines were generated and tocochromanol content of T2 seed was determined by HPLC analysis as described in Example 1 (see Table 12).

  TABLE 12
  Tocol Composition (percent of total tocopherols (tocph.) and tocotrienols (toct.))
  of T2 Seed Material of Transgenic Arabidopsis Lines Expressing
  Barley HGGT and Maize gamma-Tocopherol Methyltransferase Genes

  	alpha-	beta-	gamma-	delta-	alpha-	beta-	gamma-	delta-	tocph.	toct.
  Event ID	tocph.	tocph.	tocph.	tocph.	toct.	toct.	toct	toct.	(ppm)	(ppm)

  38	24	1	14	1	51	2	7	1	244	382
  17	33	1	12	0	50	0	4	0	327	382
  31	27	1	14	1	49	0	8	1	421	577
  3	30	0	14	0	49	0	7	0	489	626
  34	24	1	12	1	49	3	9	2	180	300
  32	32	1	12	1	49	2	4	0	347	418
  2	28	1	18	1	48	0	3	0	254	271
  35	24	1	15	1	48	2	8	1	245	348
  6	23	0	30	0	47	0	0	0	165	148
  12	17	2	7	1	47	7	16	2	388	987
  29	26	1	13	1	47	2	8	2	318	461
  25	29	1	14	1	47	2	6	1	327	407
  15	25	1	22	1	47	2	2	0	350	374
  18	27	1	16	1	46	0	8	1	344	429
  27	26	1	16	1	45	2	8	1	335	435
  33	28	1	16	1	45	0	7	1	214	246
  20	29	1	16	1	45	0	8	1	330	385
  13	28	0	17	1	44	0	9	1	356	419
  26	27	1	20	1	40	0	11	1	284	312
  30	35	1	17	1	40	0	7	1	400	354
  21	31	0	22	1	38	0	8	1	329	282
  22	14	1	11	1	38	3	29	4	358	965
  1	38	0	21	1	34	0	6	0	422	286
  5	31	0	28	0	33	0	8	0	168	117
  28	49	1	19	0	29	0	2	0	240	108
  10	22	0	39	1	29	0	9	1	260	160
  11	3	0	94	1	2	0	0	0	377	8
  23	69	0	30	1	0	0	0	0	400	2
  4	1	0	98	1	0	0	0	0	291	0
  7	17	0	82	1	0	0	0	0	311	0
  8	1	0	98	1	0	0	0	0	347	0
  9	1	0	98	2	0	0	0	0	417	0
  14	65	0	34	1	0	0	0	0	426	0
  16	1	0	98	2	0	0	0	0	266	0
  19	1	0	98	1	0	0	0	0	379	0
  24	68	1	30	1	0	0	0	0	323	0
  36	69	1	30	1	0	0	0	0	305	0
  37	1	0	97	2	0	0	0	0	262	0
  wild-type	1	0	98	1	0	0	0	0	173	0

• Of the 38 events analyzed 26 showed greater than 100 ppm tocotrienols and reached levels as high as 990 ppm. In these 26 events alpha-tocotrienol represented at least 28% and as much as 51% of the total tocochromanol content. In T2 seed of the best event (Event ID 12) alpha-tocotrienol levels reached 640 ppm (i.e., (388+987)×0.47=646). The T2 material described so far still contains 25% of wild-type seed.Events 3, 12, 29, 31 and 32 were germinated on selective media. When grown on selective media T2 seed of all six events produced 25% of kanamycin-sensitive wild-type seed. For each event 15 kanamycin resistant seedlings were transferred to soil allowed to self-fertilize and grown to maturity. For each event three T3 seed selections were identified that no longer segregated kanamycin-sensitive seedlings. This seed material was subjected to tocochromanol quantitation as described above (see Table 13).

  TABLE 13
  Tocol Composition (percent of total tocopherols (tocph.) and tocotrienols (toct.))
  of Homozygous T3 Seed Material of TransgenicArabidopsisLines Expressing
  Barley HGGT and Maize gamma-Tocopherol Methyltransferase Genes

  	alpha-	beta-	gamma-	delta-	alpha-	beta-	gamma-	delta-	tocph.	toct.
  Event ID	tocph.	tocph.	tocph.	tocph.	toct.	toct.	toct	toct.	(ppm)	(ppm)

  3	29	1	2	1	61	2	3	1	229	464
  3	33	1	2	1	58	2	3	0	493	849
  3	32	1	2	1	58	2	4	1	307	545
  12	24	2	2	1	59	7	4	1	407	971
  12	19	5	1	1	55	14	4	2	361	1031
  12	21	3	9	1	53	7	5	1	441	880
  29	23	2	2	0	58	6	7	2	345	943
  29	28	2	3	0	53	4	8	2	320	647
  29	17	2	2	0	51	7	15	5	219	770
  32	21	2	1	0	64	8	4	1	213	675
  32	22	2	1	0	63	6	4	1	291	841
  32	24	2	2	1	61	5	4	1	346	865
  31	21	2	2	2	65	3	4	1	300	795
  31	22	3	1	1	66	4	3	1	213	562
  31	21	3	2	2	63	4	5	1	297	785

• In the homozygous T3 seed material of the five events alpha-tocotrienol represented at least 51% and as much as 65% of the total tocochromanol content. In homozygous T3 seed of one event (Event ID 12) alpha-tocotrienol levels reached 810 ppm (i.e., (407+971)×0.59=813). In all five events gamma tocotrienol levels are at very low levels compared to the best transgenic event generated in similar experiments performed with the soybean GTMT sequence (Example 1). The maize GTMT provides an excellent enzyme for methylation of gamma-tocotrienol in developingArabidopsisseed.
• All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
• Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, one of ordinary skill will recognize that certain changes and modifications may be practiced and are included within the scope of the foregoing invention and the appended claims.

Claims (28)

1. A transformed plant comprising in its genome:

(a) a first recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to at least one nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence encoding a gamma-tocopherol methyltransferase;

(ii) a nucleotide sequence set forth in SEQ ID NOs: 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 or 39;

(iii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NOs:12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40;

(iv) a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence set forth in any one of (i)-(iii), wherein the nucleotide sequence encodes a gamma-tocopherol methyltransferase; and

(v) a nucleotide sequence that is fully complementary to the nucleotide sequence of any one of (i)-(iv); and

(b) a second recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to at least one nucleotide sequence selected from the group consisting of:

(vi) a nucleotide sequence encoding a homogentisate geranylgeranyl transferase;

(vii) a nucleotide sequence set forth in SEQ ID NOs:1, 3, 5, 7, or 9;

(viii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NOs:2, 4, 6, 8, or 10;

(ix) a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence set forth in any one of (vi)-(viii), wherein the nucleotide sequence encodes a homogentisate geranylgeranyl transferase; and

(x) a nucleotide sequence that is fully complementary to the nucleotide sequence of any one of (vi)-(ix),

wherein the first nucleic acid molecule and the second nucleic acid molecule are stably incorporated into the genome of the transgenic plant.

2. The transformed plant ofclaim 1, wherein the plant is a monocot.

3. The transformed plant ofclaim 2, wherein the monocot is selected from the group consisting of maize, wheat, rice, sorghum, barley, millet and rye.

4. The transformed plant ofclaim 1, wherein the plant is a dicot.

5. The transformed plant ofclaim 4, wherein the dicot is selected from the group consisting of soybean,Brassicasp., alfalfa, safflower, sunflower, cotton, peanut, canola,Arabidopsis, tobacco and potato.

6. The transformed plant ofclaim 1, wherein the at least one regulatory sequence of the first recombinant nucleic acid molecule comprises at least one promoter selected from the group consisting of seed-preferred, constitutive, chemically regulated, tissue-preferred, and developmentally regulated promoters; wherein the at least one regulatory sequence of the second recombinant nucleic acid molecule comprises at least one promoter selected from the group consisting of seed-preferred, constitutive, chemically regulated, tissue-preferred, and developmentally regulated promoters; and wherein the at least one promoter of the first recombinant nucleic acid molecule is the same as or different from the at least one promoter of the second recombinant nucleic acid molecule.

7. Seed of the transformed plant ofclaim 1, wherein said seed comprises in its genome the first recombinant nucleic acid molecule and the second recombinant nucleic acid molecule.

8. The transformed plant ofclaim 1, wherein said transformed plant produces a seed with one or both of an increased alpha- and beta-tocotrienol level relative to a plant with a similar genetic background but lacking said first recombinant nucleic acid molecule and said recombinant second nucleic acid molecule.

9. A method of increasing the level of alpha- or beta-tocotrienol in a plant, comprising: stably incorporating into its genome

(a) a first recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to at least one nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence encoding a gamma-tocopherol methyltransferase;

(ii) a nucleotide sequence set forth in SEQ ID NOs: 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 or 39;

(iii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NOs:12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40;

(iv) a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence set forth in any one of (i)-(iii), wherein the nucleotide sequence encodes a gamma-tocopherol methyltransferase; and

(v) a nucleotide sequence that is complementary to the nucleotide sequence of any one of (i)-(iv); and

(b) a second recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to at least one nucleotide sequence selected from the group consisting of:

(vi) a nucleotide sequence encoding a homogentisate geranylgeranyl transferase;

(vii) a nucleotide sequence set forth in SEQ ID NOs:1, 3, 5, 7, or 9;

(viii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NOs:2, 4, 6, 8, or 10;

(ix) a nucleotide sequence having at least 80% sequence identity to the nucleotide sequence set forth in any one of (vi)-(viii), wherein the nucleotide sequence encodes a homogentisate geranylgeranyl transferase; and

(x) a nucleotide sequence that is complementary to the nucleotide sequence of any one of (vi)-(ix).

10. The method ofclaim 9, wherein at least one of said first or second recombinant nucleic acid molecule is incorporated into the genome by transformation.

11. The method ofclaim 9, wherein at least one of said first or second recombinant nucleic acid molecule is incorporated into the genome by breeding.

12. The method ofclaim 9, wherein the at least one regulatory sequence of the first recombinant nucleic acid molecule comprises at least one promoter selected from the group consisting of seed-preferred, constitutive, chemically regulated, tissue-preferred, and developmentally regulated promoters; wherein the at least one regulatory sequence of the second recombinant nucleic acid molecule comprises at least one promoter selected from the group consisting of seed-preferred, constitutive, chemically regulated, tissue-preferred, and developmentally regulated promoters; and wherein the at least one promoter of the first recombinant nucleic acid molecule is the same as or different from the at least one promoter of the second recombinant nucleic acid molecule.

13. A method of increasing the level of alpha- or beta-tocotrienol in a plant, comprising:

(a) obtaining a first plant comprising in its genome a first recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to a nucleotide sequence encoding a gamma-tocopherol methyltransferase; and

(b) crossing the transgenic plant of step (a) with a second plant comprising in its genome a second recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to a nucleotide sequence encoding a homogentisate geranylgeranyl transferase gene; and

(c) obtaining a progeny plant from said step (b) crossing, wherein said progeny plant comprises in its genome the first recombinant nucleic acid molecule and the second recombinant nucleic acid molecule, and wherein said progeny plant exhibits increased levels of alpha- or beta-tocotrienol.

14. A method of increasing the level of alpha- or beta-tocotrienol in a plant, comprising:

(a) obtaining a first plant comprising in its genome a first recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to at least one nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence encoding a gamma-tocopherol methyltransferase;

(ii) a nucleotide sequence set forth in SEQ ID NOs:11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 or 39;

(iii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NOs:12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40;

(iv) a nucleotide sequence having at least 80% sequence identity to the entire coding sequence of the nucleotide sequence set forth in any one or (i)-(iii), wherein the nucleotide sequence encodes a gamma-tocopherol methyltransferase; and

(v) a nucleotide sequence that is complementary to the nucleotide sequence of any one of (i)-(iv); and

(b) crossing the transgenic plant of step (a) with a second plant comprising within its genome a second recombinant nucleic acid molecule comprising at least one regulatory sequence operably linked to at least one nucleotide sequence selected from the group consisting of:

(vi) a nucleotide sequence encoding a homogentisate geranylgeranyl transferase;

(vii) a nucleotide sequence set forth in SEQ ID NOs:1, 3, 5, 7 or 9;

(viii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NOs:2, 4, 6, 8 or 10;

(ix) a nucleotide sequence having at least 80% sequence identity to the entire coding sequence of the nucleotide sequence set forth in (vi)-(viii), wherein the nucleotide sequence encodes a homogentisate geranylgeranyl transferase; and

(x) a nucleotide sequence that is complementary to the nucleotide sequence of any one of (vi)-(ix)

(c) obtaining a progeny plant from said step (b) crossing, wherein said progeny plant comprises in its genome the first recombinant nucleic acid molecule and the second recombinant nucleic acid molecule, and wherein said progeny plant exhibits increased levels of alpha- or beta-tocotrienol.

15. The method of claims9,13 or14, wherein the plant is a monocot.

16. The method ofclaim 15, wherein the monocot is selected from the group consisting of maize, wheat, rice, sorghum, barley, millet and rye.

17. The method of claims9,13 or14, wherein the plant is a dicot.

18. The method ofclaim 17, wherein the dicot is selected from the group consisting of soybean,Brassicasp., alfalfa, safflower, sunflower, cotton, peanut, canola,Arabidopsis, tobacco and potato.

19. Transformed seed or byproducts thereof of the plant of claims9,13 or14.

20. The seed ofclaim 19, wherein the seed has an alpha-tocotrienol level of at least 20 ppm.

21. The seed ofclaim 19, wherein the seed contains alpha-tocotrienol in an amount of at least 20% of total tocopherol and tocotrienol content in the seed.

22. A method of improving the tissue quality of an animal, comprising feeding the animal the transformed seed ofclaim 19.

23. The method ofclaim 22, wherein the tissue is meat and the quality of the meat is measured by criteria selected from the group consisting of increased pH, improved food color, improved oxidative stability, increased shelf life and reduced purge.

24. The method ofclaim 22, wherein the animal is a ruminant.

25. The method ofclaim 24, wherein the animal is cattle.

26. The method ofclaim 22, wherein the animal is a non-ruminant.

27. The method ofclaim 26, wherein the animal is swine or poultry.

28. An isolated polynucleotide comprising SEQ ID NO:43.

Images